Tag Archives: Medical Research

Progenabiome Shares New Data on Fecal Transplant, Sars-Cov-2 at ACG 2020

VENTURA, Calif. /ScoopCloud/ -- The American College of Gastroenterology (ACG) named Progenabiome "Outstanding Poster Presenter" for its poster: "Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection," which will be presented virtually at the ACG Annual Scientific Meeting this week. From close to 2900 posters, only roughly 10% were selected as outstanding posters.

Progenabiome will also present a second poster: "Detection and Mutational Analysis of SARS-CoV-2 From Patient Fecal Samples by Whole Genome Sequencing." The ACG 2020 Meeting will be held virtually on October 23-28, 2020, and both poster abstracts and presentations will be available online in the ACG 2020 ePoster Hall.

Last year, Dr. Sabine Hazan, CEO of Progenabiome, shared groundbreaking data on C.Diff discovered through genetic sequencing at the 2019 ACG Meeting. She is looking forward to sharing newly found data on C.Diff and also COVID-19 at this year's event.

Dr. Hazan also recently published new findings from a phase 2 trial on Eosinophilic Gastritis and Duodenitis in the New England Journal of Medicine (NEJM.) As a leading clinical trials investigator who has overseen more than 150 clinical trials, Dr. Hazan is dedicated to research and producing validated, verified, and reproduced data.

Strategically placed as a genetic sequencing lab, site, contract research organization (CRO), and now sponsor, Progenabiome has 41 ongoing clinical trials related to immunity and disease, including five COVID-19 studies validating testing, prophylaxis, and at-home treatment protocols for the novel coronavirus.

For more information, visit:
https://progenabiome.com

https://clinicaltrials.gov

https://malibumicrobiomemeeting.com/

ACG ePoster Hall: https://eventscribe.com/2020/ACGPosters/

NEJM paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2012047

Media Contact:
Stephanie Davis
sdavis@progenabiome.com

*IMAGE Link for Media: https://www.Send2Press.com/300dpi/20-1026s2p-Progenabiome-data-300dpi.jpg

The American College of Gastroenterology (ACG) named Progenabiome "Outstanding Poster Presenter" for its poster: "Successful Bacterial Engraftment Identified by Next Generation Sequencing Following Fecal Microbiota Transplantation for Clostridioides difficile Infection," which will be presented virtually at the ACG Annual Scientific Meeting this week.

Related link: https://progenabiome.com/

Alzheimer’s Patient Recalls Daughter’s Birthday After Undergoing Fecal Transplant

VENTURA, Calif. /ScoopCloud/ -- Dr. Sabine Hazan, founder of ProgenaBiome, a genetic sequencing lab in California, achieved rapid improvement in Alzheimer's disease (AD) symptoms in an 82-year-old male patient following fecal microbiota transplantation (FMT).

After experiencing recurrent C.diff Infection (CDI) following hospitalization for pneumonia, the patient sought the expertise of Dr. Hazan, a gastroenterologist and microbiome expert. Since the patient previously failed several courses of antibiotics for CDI, with relapse confirmed via symptom recurrence and positive stool test, Dr. Hazan presented the option of fecal transplant (FMT). FMT involves the transfer of stool from a healthy individual to deliver healthy microbes to the gut of an ill patient. FMT can be used to treat CDI not responsive to standard therapies.

After a detailed discussion regarding the potential risks and benefits associated with the procedure, the patient underwent a single 300 mL FMT infusion using stool from his 85-year-old wife as a donor. At the time, the patient had scored 20 on his most recent Mini-Mental State Examination (MMSE) administered by a neurologist, indicating mild cognitive impairment. The patient's wife, on the other hand, was intellectually acute, with normal affect and stable mood.

Following the procedure, the patient's CDI symptoms resolved, and repeat stool testing two months later was negative. Additionally, the patient's wife reported improvements in his mental acuity and affect at the follow-up visit two months post-FMT. The MMSE was re-administered by the gastroenterologist and neurologist, and the patient scored 26, indicating normal cognition.

Four months post-FMT, the patient reported continued improvement in memory, with no progression in symptoms. The patient even remembered his daughter's birthday, which he was previously unable to recall. Six months post-FMT, the patient reported a marked improvement in mood, was more interactive, and showed more expressive affect. Readministration of the MMSE revealed that the patient's score had further increased to 29. The maximum MMSE score is 30 points.

Dr. Hazan is a specialist in gastroenterology, internal medicine and hepatology. She is the founder & CEO of ProgenaBiome, a genetic sequencing research laboratory dedicated to understanding the clinical implications of the microbiome.

"To our knowledge, this is the first report of a case of rapid symptom improvement of AD symptoms in a patient following FMT for recurrent CDI," says Dr. Hazan. "Based on the findings of this case and the analysis of the genetic sequencing of the gut flora, we will now submit an investigative new drug (IND) application for 20 additional Alzheimer's patients to undergo fecal transplant. We hope to reproduce this case and develop a stool marker that can help patients prevent Alzheimer's in the future."

While this case is a proof of concept for one patient, Dr. Hazan looks forward to expanding her work. She is currently seeking funding to expand the clinical trial for Alzheimer's improvement via FMT.

Dr Hazan also assembled the BIOME SQUAD, a group of her colleagues and fellow FMT doctors. The Biome Squad will be presenting data on the microbiome and fecal transplant at the Malibu Microbiome Meeting.

There will be a Virtual Prelude Rerun on October 14, 4 p.m. PT/PDT. For details and registration, visit: https://malibumicrobiomemeeting.com/

Read the full Alzheimer's report: https://journals.sagepub.com/doi/10.1177/0300060520925930

Interviews / Investors, Contact: Stephanie Davis, sdavis@progenabiome.com

Support ongoing research: https://microbiomeresearchfoundation.com/

About ProgenaBiome:

Strategically placed as a genetic sequencing lab, site, contract research organization (CRO), and now sponsor, ProgenaBiome has 42+ ongoing clinical trials related to immunity and disease with six COVID-19 studies validating testing, prophylaxis, and treatment protocols for the novel coronavirus.

For more, visit https://progenabiome.com

MULTIMEDIA:

Image link for media: https://www.Send2Press.com/300dpi/20-1006s2p-malibu-microbiome-300dpi.jpg

Caption: Malibu Microbiome Meeting poster.

Dr. Sabine Hazan, founder of ProgenaBiome, a genetic sequencing lab in California, achieved rapid improvement in Alzheimer's disease (AD) symptoms in an 82-year-old male patient following fecal microbiota transplantation (FMT).

Related link: https://progenabiome.com/

NED Biosystems Announces Leading Infectious Disease Research Scientist Michael Mansour, MD, PhD To Serve as Medical Advisor

CAMBRIDGE, Mass. /ScoopCloud/ -- NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour, MD, PhD, will serve as the Company's Medical Advisor of Infectious Disease. Dr. Mansour brings a wealth of expertise in infectious disease research where he leads an independent laboratory at the Massachusetts General Hospital (MGH). He is a leading authority guiding investigative studies on COVID-19 treatments and biomarkers which includes serving as Principal Investigator for Phase 3 COVID-19 studies.

As Medical Advisor, Dr. Mansour will direct NED's clinical trial initiative for NED-260 to establish the treatment's safety and efficacy for COVID-19 patients. NED-260 is a rationally designed, combination treatment that has the potential to address COVID-19 viral replication and entry based on its multiple mechanisms of action. Through its multifaceted approach to address major processes integral to COVID-19's progression and how it infects the cell, NED-260 may fulfill a critically important niche in the treatment and prevention of mild-to-moderate illness in the majority of people who are at risk for COVID-19 infection. NED is planning to conduct a Phase 2, randomized, placebo-controlled study of NED-260 in mild-to-moderate COVID-19 patients.*

"This study offers a chance to look at an oral treatment for COVID-19," said Dr. Mansour. "Taken directly after diagnosis, the combination is aimed at interrupting disease progression - and potentially speeding up a patient's recovery time. The trial will also explore the use of NED-260 as a potential prophylaxis, to prevent infection."

"The contribution of Dr. Mansour's expertise and considerable insight will be invaluable as we establish the safety and efficacy of NED-260 as a COVID-19 treatment," stated Rebecca Lambert, Founder and Executive Chair of NED Biosystems. "We are eager to commence the NED-260 clinical trials with Dr. Mansour's seasoned guidance. The time is now to develop an early treatment solution and preventative of infection."

"Dr. Mansour is an outstanding addition to our team of accomplished medical advisors at NED Biosystems," stated Dr. Geoffrey Ling, Office of the CEO, Scientific Advisory Board, Board of Directors, NED Biosystems and advisor to the U.S. Government's COVID-19 Task Force. "His prominence in the field of infectious disease research and deep expertise will help propel our efforts to bring our uniquely comprehensive treatments to the broader patient community. We are delighted to welcome him to the team."

Dr. Mansour leads a team of medical research scientists at the Mansour Laboratory that focuses on developing novel cellular diagnostics and therapies for invasive fungal infections. He is also a practicing physician specialized in infectious disease at MGH. Dr. Mansour obtained an MD and PhD from Boston University and completed his residency and served as a fellow at the MGH.

About NED Biosystems(TM)

Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company developing innovative treatments to provide multifaceted approaches to affect multiple key disease processes. Beginning with a focus on patients and their families, NED seeks to dramatically improve patient outcomes with combination treatments comprised of agents with well-established safety and tolerability profiles. NED's treatment approach is to afford patients high quality of life. Due to ease of oral dosing and cost-effectiveness of the treatments, the company aims to provide revolutionary, efficacious treatment solutions to patients not only in the U.S. and other developed nations, but also in economically challenged regions globally.

For more information, visit https://nedbiosystems.com/.

For additional information regarding this press release, please contact Creative Director, Brett Macias at bmacias@nedbiosystems.com.

*NED-260 is pending approval by the FDA post clinical trials.

PHOTO link for media: https://www.Send2Press.com/300dpi/20-1006s2p-ned-michael-mansour-300dpi.jpg

Caption: Michael Mansour, MD, PhD, NED Biosystems' New Medical Advisor of Infectious Disease.

NED Biosystems, an innovative clinical-stage biotech company developing therapies for cancer and the novel coronavirus, is pleased to announce that Michael Mansour, MD, PhD, will serve as the Company's Medical Advisor of Infectious Disease.

Related link: https://nedbiosystems.com/

Leading Experts in Cancer Research Nabeel El-Bardeesy and Razelle Kurzrock Join NED Biosystems’ Scientific Advisory Board

CAMBRIDGE, Mass. /ScoopCloud/ -- NED Biosystems, an innovative clinical-stage biotech company developing oral therapies for cancer and novel coronavirus, is pleased to announce that Nabeel El-Bardeesy, PhD and Razelle Kurzrock, MD have joined the Company's Scientific Advisory Board. Both Dr. El-Bardeesy and Dr. Kurzrock bring a wealth of expertise as scientific and clinical leaders in cancer research and treatments.

Dr. El-Bardeesy is Associate Professor of Medicine at the Harvard Medical School and a leading authority on the causes of cancer. Dr. El-Bardeesy also serves as the Cholangiocarcinoma Foundation Scientific and Medical Advisory Board Co-Chair. Dr. El-Bardeesy additionally is Assistant Professor at Massachusetts General Hospital Cancer Center and is an instructor at the Dana-Farber Cancer Institute. Dr. El-Bardeesy is widely published on the molecular and cellular mechanisms that drive certain types of cancer.

Dr. Kurzrock is Professor of Medicine and Associate Director for Clinical Sciences at the University of San Diego Moore Cancer Center. She leads the Center's clinical trial programs and heads its recently established Center for Personalized Cancer Therapy. Dr. Kurzrock's distinguished track record includes leading one of the largest phase one clinical trial programs at the University of Texas MD Anderson Cancer Center, where she spearheaded an innovative approach that utilized advanced molecular technologies to match patients with targeted cancer treatment that optimized the possibility for response.

"The addition of Dr. El-Bardeesy and Dr. Kurzrock to the Scientific Advisory Board further strengthens the resolve of NED's mission to innovate safe, effective and transformative treatments for cancer and other life-threatening diseases such as Covid-19," stated Rebecca Lambert, Founder and Executive Chair of NED Biosystems' Board. "As we advance NED-170 clinical trials for cholangiocarcinoma, ovarian and triple negative breast cancer to establish the product's safety and efficacy, we will rely heavily on the Scientific Advisory Board's expert guidance and direction. They will also play an instrumental role in our efforts to launch clinical trials for NED-260, a potential treatment and prophylaxis for COVID-19.*"

NED-170 is a patented investigational cancer therapy that the Company believes is the first to address and affect four key processes that advance all late-stage cancers (Stages II-IV). The same four processes that drive advanced cancers are integral to the pathology of Covid-19.

"The implementation of comprehensive clinical trials is a vitally important step in determining the safety and effectiveness of the treatments for life threatening illnesses that we are innovating at NED Biosystems," stated Geoffrey Ling, COL(ret) MD, PhD, Office of the CEO, and member of the Scientific Advisory Board and Board of Directors, NED Biosystems and member of the U.S. Government's Covid-19 Task Force. "The deep expertise of our Scientific Advisory Board provides us with the confidence that we are following the proper methods and techniques to generate a valid set of trial results."

"Dr. Kurzrock and Dr. El-Bardeesy will provide invaluable guidance on the clinical design and execution for our upcoming NED-170 trials, as well as input into the analysis of the results," stated Brian Leyland-Jones, BS, MBBS, PhD, FRACP, FRACPC, NED Biosystems Chair of the Scientific Advisory Board. "We are excited to welcome them to the Scientific Advisory Board and look forward to their support of our clinical trial initiatives."

About NED Biosystems(TM)

Based in Cambridge, Massachusetts, NED Biosystems is a clinical-stage biotech company developing innovative treatments unlike most available today. Beginning with a focus on patients and their families, NED seeks to dramatically improve patients' outcomes with therapies that lack the toxicity and side effects of today's treatments, allowing patients to retain a high quality of life. Due to ease of oral dosing and cost-effectiveness of the treatments, the company aims to provide revolutionary, efficacious treatment solutions to patients not only in the U.S. and other developed nations but also in economically challenged global regions.

For more information, visit https://nedbiosystems.com/.

For additional information regarding this press release, please contact Creative Director, Brett Macias at bmacias@nedbiosystems.com.

*NED-170 and NED-260 are pending approval by the FDA post clinical trials.

*LOGO link for media: https://www.Send2Press.com/300dpi/20-0902s2p-nedbio-300dpi.jpg

NED Biosystems, an innovative clinical-stage biotech company developing oral therapies for cancer and novel coronavirus, is pleased to announce that Nabeel El-Bardeesy, PhD and Razelle Kurzrock, MD have joined the Company's Scientific Advisory Board.

Related link: https://nedbiosystems.com/

Zeblok Computational Announces Partnership with Laufer Center and CEWIT – COVID-19 Drug Discovery

STONY BROOK, N.Y. /ScoopCloud/ -- Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok's secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster.

The Laufer Center simulations focus on 3 key proteins of the SARS-CoV-2 virus to pinpoint more precisely which drug candidates have the best binding affinity to various protein targets:
1. The RNA-dependent RNA polymerase (which copies the virus inside the cell, thought to be the target of Gilead's Remdesivir, now in clinical trials)
2. The Protease (which chops up the virus proteins into the right pieces)
3. The spike protein (which is how the virus unlocks the door to enter the cell).

The Laufer Center is running their computationally-intense simulations to understand how proteins fold and how proteins bind to proteins - actions, mechanisms and binding affinities - to enable design of drugs for high-affinity binding to proteins. They apply state-of-the-art modeling, using physics-based methods to examine motions, forces and free energies within biological mechanisms. In a previous limited benchmarking program, the Laufer Center concluded that they achieved a 6x improvement in performance on Zeblok's platform compared to NSF's Blue Waters Cray GPU-based system. The structures of most COVID virus proteins are not yet known. Dr. Ken Dill's group is computing many of their structures using MELD x MD, while Dr. Dima Kozakov's group is computing structures of human-virus and virus-virus protein pairs.

"Companies offering in silico drug discovery services, such as computer-aided drug design (CADD), molecular modeling and quantitative structure-activity relationship (QSAR), have now become an important part of the pharmaceutical industry. Drug developers, especially those focused on the development of large molecules, are likely to continue relying on outsourcing for a significant part of their respective drug discovery and development operations. Zeblok Computational platform levels the playing field for researchers that need accelerated infrastructure for R&D. We uniquely combine computing platforms, orchestration, multi-cloud and in silico software developers to deliver quality services for companies engaged in drug discovery," said Zeblok Computational CEO Mouli Narayanan.

Zeblok Computational is incubated at and supported by CEWIT, using its SMART cluster of 180 NVIDIA RTX 6000 GPUs. "Our dual-use homogenous SMART Cluster is one of the fastest GPU clusters in academia and supports dual-use of both deep learning and visualization in a variety of applications," said Dr. Arie Kaufman, the Chief Scientist and the SMART Cluster Director.

Mr. Narayanan further said, "We want to help data center operators at the grass roots level to offer AI and AI-Hyperconvergence capabilities to their customers, enabling them to participate in the AI ecosystem. Companies are confronted with so much data that they increasingly need AI enabled smart processes. Implementation of 5G is further driving the low latency requirement for AI-Inferencing at Edge data centers. Zeblok's orchestration engine seamlessly integrates multiple disparate resources into a complete AI model development environment all the way to the Edge, supported by its smart sourcing business model for surplus GPU capacity."

About Zeblok Computational

Zeblok Computational Inc. is an Artificial Intelligence Platform-as-a-Service, providing a single unified pre-configured environment, with familiar frameworks and languages as well as a growing library of carefully selected proven original AI algorithms, enabling data scientists to begin developing AI models in minutes, to scale effortlessly for model training and to deploy in a runtime environment, with AI expertise and high touch assistance in integrating AI solutions into enterprise business processes.

Zeblok's container-based engineering platform leverages familiar open source software, adding a sophisticated proprietary multi-class, multi-cloud orchestration engine that combines heterogeneous environments through abstraction and virtualization and includes built-in resource management, multi-tier workload distribution, both front-end and back-end services and scale-out resource availability in minutes. Zeblok's secure, smart sourced, Edge-connected accelerated infrastructure comprises a multi-cloud of over 7,000 GPUs, enabled by partnerships with the CEWIT and others.

For more information: https://www.computational.zeblok.com/

About The Laufer Center

The Louis and Beatrice Laufer Center, established in 2008 to advance biology and medicine through discoveries in physics, mathematics and computational science, is a hub for Physical and Quantitative Biology research at Stony Brook University. Laufer Center researchers come from several Stony Brook departments and Cold Spring Harbor Laboratory.

For more information: https://laufer-covid.org/ and http://laufercenter.stonybrook.edu/

About CEWIT

New York's Center of Excellence in Wireless and Information Technology (CEWIT) at Stony Brook University is a next-generation research and educational facility with a mission to conduct interdisciplinary applied research in emerging and critical technologies, address the skilled technology worker shortage and to foster new enterprise development in wireless and IT communications, infrastructure, networking, and software. When CEWIT upgraded its accelerated infrastructure to a smart cluster of over 180 NVIDIA RTX 6000 GPUs in 2019, they realized they needed to orchestrate the various resources to achieve seamless distribution of compute power throughout the university, which led to its partnership with Zeblok.

For more information: https://www.cewit.org/

*LOGO link for media: https://www.Send2Press.com/300dpi/20-0720-zeblok-logo-300dpi.jpg

Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok's secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster.

Related link: https://www.computational.zeblok.com/

ROKiT Pharma’s Preclinical Studies Showing Tremendous Promise for Naturally Derived Cancer Drug, ROK-001 – Moving Towards The Initiation Of Phase 1b/2 Clinical Trial

LOS ANGELES, Calif. /ScoopCloud/ -- ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.

During the Phase 1b trial, ROKiT Pharma's goal will be to determine the safety and tolerability of the drug in humans, as well as understand the pharmacokinetic and pharmacodynamic properties. If ROK-001 gains IND approval, ROKiT Pharma would like to open its first clinical trial during the summer of 2020. Discussions are currently underway with two prominent hospitals for this trial.

"The University of Sydney found the naturally occurring compounds on Kangaroo Island, we then completed our multiyear process of developing the synthetic processes and patenting the compound and related analogs," said Dean Becker, chairman and CEO of ROKiT Pharma and globally recognized leader in IP strategy. "Our plan is to produce large quantities of the drug - enough for universal need - so that we can really help people combat this disease through more natural sources. Unleashing nature is our goal - we want to provide these potentially life prolonging drugs, in oral pill form, at a projected cost under $1,500 per month."

The patented chemical platform of ROKiT Pharma's key drugs have unprecedented in vitro and in vivo efficacy on 29 major types of cancer (intriguingly, showing activity on p53, AP-1, and NF-kB). Importantly, selective toxicity of ROK-001 on cancer cells rather than non-neoplastic (healthy) cell lines account for its' high therapeutic index, while safety profile evaluations confirm that the compound exerts no genotoxicity nor cardiotoxicity.

Given these results, ROKiT Pharma narrowed its focus for its' first clinical trial to some of the worst cancers that have no current cure - pancreatic and brain (specifically Glioblastoma Multiforme and patients who have had metastases to the brain from other organs).

"Once ROKiT Pharma is able to get FDA approval in one adult cancer type, we plan to divert our focus to childhood cancers," said John Paul DeJoria, ROKiT co-founder and founder of Paul Mitchell Systems and Patron Tequila. "As ROKiT continues to grow globally, we are continuing to add companies that really fulfill our humanitarian goals. Success unshared is failure."

The naturally derived anticancer compounds used to create ROK-001 were discovered through the propolis of Ligurian honey bees only found on Kangaroo Island, which lies off the mainland of South Australia. Propolis is a mixture of beeswax, saps and resins.

In animal studies, ROK-001 demonstrated great efficacy in a multitude of cancer models including pancreatic, melanoma, kidney, bladder, and breast, some in as early as seven days post-oral treatment. Aside from efficacy information, ROK-001 was specifically formulated for oral delivery that not only demonstrated nice biodistribution, but it also revealed that ROK-001 can cross the blood-brain barrier in mice. This discovery led to the decision to target brain cancers.

ROKiT Pharma hopes to fast track this relatively low-toxicity drug for patients with the most deadly cancers. With any proven efficacy in the Phase 1b clinical trial, the FDA may allow an immediate Phase 2 trial to start with an expanded cohort and patient population.

Upon IND approval of ROK-001, the company plans to make the drug available for "Compassionate Use" as is now allowed under the "Right To Try Act" that President Trump signed in 2018.

ROKiT Pharma is presently designing and planning a manufacturing facility (or contract manufacturing facility) in Puerto Rico to act as an established hub for global distribution.

"As the ROKiT brand's awareness continues to grow through our global sports sponsorships - ROKiT Williams Racing Formula 1, ROKiT Venturi Racing Formula E, the Houston Rockets, the Las Vegas Raiders - we are elated to be aggressively entering the pharmaceutical marketplace," said Jonathan Kendrick, co-founder of ROKiT.

The company is optimistic that ROK-001 will move straight into at least one Phase 2 trial and is currently adding philanthropic investors to its capital base.

If there is interest in learning more about ROKiT Pharma or for philanthropic inquiries, please contact info@rokitpharma.com for further information.

About ROKiT Pharma

ROKiT Pharma is a late stage preclinical pharma company focusing its research efforts on cancer. The corporation has an extensive global intellectual property portfolio. Research was developed at and in conjunction with the University of Sydney.

Additional information (*new site under construction Q2/2020): https://www.rokitpharma.com/

Media Contact:
Kristyn Clark
Senior PR Manager
ROKiT Pharma
Tel: (805) 231-1572
kristyn.clark@rokit.com

*LOGO link for media: https://www.Send2Press.com/300dpi/20-0402s2p-rokit-pharma-300dpi.png

ROKiT Pharma, Inc., a public-benefit corporation dedicated to putting patients first, announced today it is rapidly progressing through final preclinical studies and moving forward with preparation for the initiation of a Phase 1b/2 clinical trial of ROK-001, a potentially low toxicity cancer drug derived from natural ingredients.

Related link: https://www.rokitpharma.com/

Treating Schizophrenia with Individualized Care

YAP, Micronesia /ScoopCloud/ -- Schizophrenia may find a cure in individualized treatment. So says a new article in the science journal Holistic Nursing Practice. According to Dr. Daniel Helman, a researcher on the small island of Yap in Micronesia, long-term recovery is often possible, but appropriate studies are not being done.

Helman teaches at the College of Micronesia-FSM, in their division of education. He recently assessed the evidence-based literature related to schizophrenia. While there are promising avenues related to diet, exercise, and social roles that have some anecdotal support, treatment remains difficult because large, randomized trials are not being carried out.

"[P]sychiatric medications include major health risks from effects that appear during long-term adherence," Helman writes, while many other non-medical treatments remain promising, awaiting further study. None of the existing studies of nonmedical treatment ideas are large enough to be conclusive. "For example, having a [coach or personal trainer] help with 20 hours of exercise per week, the evidence base needs to be more complete so that funding for supports such as this can be instituted."

One rarely sees people suffering from the major symptoms of schizophrenia who have such an intensive exercise routine, according to Helman, so a path for future studies is likely to be useful.

Moreover, dietary interventions which could target autoimmune features, or vitamin or mineral deficiencies, or abnormal lipid metabolism, or gluten sensitivity await further study, and in the meantime long-term outcomes for those suffering from schizophrenia are not as good as they might be.

Helman has published several articles related to alternative and complementary treatments, but resistance, according to him, may be based on how medical practitioners think about the disease. Medications to mask the symptoms may be less effective in the long-term than finding a tailored solution to each patient by looking at them as an individual within a context.

Helman's "Nonmedical Interventions for Schizophrenia: A Review of Diet, Exercise, and Social Roles" is featured in the March/April 2020 issue of the peer-reviewed journal Holistic Nursing Practice which is part of the Web of Science. Read here: https://journals.lww.com/hnpjournal/Abstract/2020/03000/Nonmedical_Interventions_for_Schizophrenia__A.2.aspx

Follow Helman on Twitter at: https://twitter.com/HelmanDaniel

Schizophrenia may find a cure in individualized treatment. So says a new article in the science journal Holistic Nursing Practice. According to Dr. Daniel Helman, a researcher on the small island of Yap in Micronesia, long-term recovery is often possible, but appropriate studies are not being done.

Related link: https://twitter.com/HelmanDaniel

Generous Bequests Help Strengthen Komen Dallas Co. Mission

DALLAS, Texas /ScoopCloud/ -- Susan G. Komen Dallas County (Komen Dallas County) today said it has received bequests from the Estate of Edith Beutell and the Estate of Dr. Glenn Dodwell, which combined total more than $199,000. The gifts will further the organization's ability to assess the state of breast health in Dallas County and create plans of action to reduce breast cancer mortality disparities in the community. In addition, the gifts allow Komen Dallas County to focus on its pillars of Research, Care, Community and Action.

"We are moved by the thoughtfulness of Mrs. Beutell and Dr. Dodwell to include Komen Dallas County in their planned estate giving and are honored to be part of their lasting legacies. This remarkable generosity allows us to hold our place as the local source for funding breast cancer detection, support and education for uninsured and underinsured women and men in Dallas County," said Sofia Olivarez, executive director of Susan G. Komen Dallas County.

The bequests ($189,893 from the Dodwell Estate and $10,000 the Beutell Estate) will help fund local breast health services and further groundbreaking research for the cures. According to her family, Mrs. Beutell was inspired by a niece's battle against breast cancer.

The gifts come as Komen Dallas County prepares to award grants for its FY2021 funding cycle. Health and community service organizations have submitted hundreds of grant requests to support programs for women and men across Dallas County using data from Komen Dallas County's recently-updated Community Profile Report as a guide.

"Komen Dallas County has identified areas within our community where gaps in access to care and health disparities persist. Planned gifts like those from Ms. Beutell and Dr. Dodwell allow us to provide vital resources to organizations that are on the frontlines working to provide education and life-saving services to those Dallas County residents who are most in need," said Daniel Jones, president of the Komen Dallas County Board of Directors.

Grant awards will be announced in April. Visit https://komen-dallas.org/grants to learn about the impact of Komen Dallas County Community Partner grants.

About Susan G. Komen® Dallas County

Komen Dallas County is committed to Dallas' fight against breast cancer. Since its inception, Komen Dallas County has invested over $27.5 million in local breast health programs providing education, screening, diagnostic services, treatment, patient navigation and transportation services. Komen Dallas County has also invested nearly $8.5 million in national, cutting edge research to find the cures so that future generations will not have to face this devastating disease.

About five Dallas County families per week can expect to lose a loved one to breast cancer. Fundraising or donations to Komen Dallas County helps the organization save a mother, daughter, sister or friend from this devastating disease. Learn more at: https://komen-dallas.org/

Reach out to us at 214-750-7223 or at info@komen-dallas.org for help or to access breast health resources.

MEDIA CONTACT
Brittani Ball
Susan G. Komen Dallas County
469-619-3904
brittaniball@komen-dallas.org

Susan G. Komen Dallas County (Komen Dallas County) today said it has received bequests from the Estate of Edith Beutell and the Estate of Dr. Glenn Dodwell, which combined total more than $199,000. The gifts will further the organization's ability to assess the state of breast health in Dallas County and create plans of action to reduce breast cancer mortality disparities in the community.

Related link: https://komen-dallas.org/

Lyme Disease Biobank Expands Into San Diego

SAN DIEGO, Calif. /ScoopCloud/ -- Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the opening of the San Diego collection site of the Bay Area Lyme Foundation's Lyme Disease Biobank, which is the first program to provide researchers with blood and urine samples from people with early Lyme disease from multiple endemic regions across the country.

Congressman Scott Peters and Councilmember Chris Cate are scheduled to speak at the ribbon-cutting ceremony for the new collection site, and Council President Pro Tem Barbara Bry, Senator Toni Atkins, and Assemblymember Todd Gloria will send representatives to issue commendations to support this event.

"Lyme disease is a growing problem in the County of San Diego, because many of our residents travel to or relocate from other more highly endemic areas and it is also possible to be infected locally," said Sharon Wampler, PhD, who was instrumental in bringing Bay Area Lyme Foundation's Lyme Disease Biobank to San Diego. "As a world-class hubfor research and innovation, we can be part of the solution. This biobank is an important resource which will help researchers answer many current scientific questions about tick-borne diseases."

Much research into tick-borne infections is needed, as current diagnostics are inaccurate for more than half of early stage Lyme disease cases, treatments do not work for everyone and late stage Lyme disease can become nearly impossible to cure. In fact, a recent study based on the samples collected by the Lyme Disease Biobank and published in the Journal of Clinical Microbiology, a journal of the American Society for Microbiology, found that the Centers for Disease Control's standard two-tier testing algorithm for Lyme disease failed to accurately diagnose 71% of blood samples from individuals in endemic areas presenting with a Lyme rash, also known as an erythema migrans, greater than 5 cm. In striving to investigate better diagnostics and treatments for tick-borne diseases, researchers require verified blood, urine and tissue samples to use in their studies.

Currently, there are 50 research projects that rely on Lyme Disease Biobank samples. The San Diego collection center will be in partnership with Osteopathic Medical Associates of San Diego (OMASD).

"As Lyme disease grows in prevalance, we are seeing more people looking to make a difference for current and future patients, and our biobank offers a valuable way for the public to support researchers who are working to find solutions," said Liz Horn, PhD, principal investigator, Lyme Disease Biobank. "We are honored to be able to give people from San Diego the opportunity to contribute to this important initiative."

The Lyme Disease Biobank in San Diego will collect from people who have ongoing symptoms of Lyme disease. Importantly, because bacterial strains of tick-borne diseases have been shown to vary from region to region, a biobank in San Diego will allow researchers to explore potential new diagnostics against the range of bacterial strains prevalent in people with Lyme disease in San Diego, along with those from other parts of the country.

San Diego residents are also invited to register for the Biobank's tissue collection program. This program allows for a greater understanding of the ability of Lyme bacteria to invade tissues and organs. The Lyme Disease Biobank is the only national entity working to accelerate research by collecting surgical and post-mortem tissue samples from individuals with persistent Lyme disease and other tick-borne infections.

Also in support of Lyme disease research such as this, community members will come together tonight, Friday, March 6 for Ride Out Lyme California at SoulCycle in La Jolla.

About Lyme Disease Biobank

The Lyme Disease Biobank (LDB), a program of the Bay Area Lyme Foundation, is a non-profit organization working to accelerate research of Lyme disease and other tick-borne infections. With a collection of biological samples from more than 900 participants, including serum, blood, urine and tissue, LDB provides much-needed samples to researchers working to better understand tick-borne diseases and develop improved tests and therapeutics. Blood and urine samples are collected from the Northeast, Upper Midwest and West Coast areas of the U.S., and tissue samples are collected throughout the country.

Healthcare providers looking to get involved, and patients interested in donating blood, urine or tissue samples can learn more here - https://www.bayarealyme.org/our-research/biobank/patient-information/

Researchers interested in obtaining samples should visit https://www.bayarealyme.org/ or contact info@lymebiobank.org.

About Lyme Disease

The most common vector-borne infectious disease in the country, Lyme disease is a potentially disabling infection caused by bacteria transmitted through the bite of an infected tick to people and pets. If caught early, most cases of Lyme disease can be effectively treated, but it is commonly misdiagnosed due to lack of awareness and unreliable diagnostic tests. There are more than 400,000 new cases of Lyme disease each year, according to statistics released in 2018 by the CDC. As a result of the difficulty in diagnosing and treating Lyme disease, more than one million Americans may be suffering from the impact of its debilitating long-term symptoms and complications, according to Bay Area Lyme Foundation estimates.

About Bay Area Lyme Foundation

Bay Area Lyme Foundation, a national organization committed to making Lyme disease easy to diagnose and simple to cure, is a leading public not-for-profit sponsor of innovative Lyme disease research in the U.S. A 501c3 non-profit organization based in Silicon Valley, Bay Area Lyme Foundation collaborates with world-class scientists and institutions to accelerate medical breakthroughs for Lyme disease. It is also dedicated to providing reliable, fact-based information so that prevention and the importance of early treatment are common knowledge. A pivotal donation from The LaureL STEM Fund covers overhead costs and allows for 100% of all donor contributions to Bay Area Lyme Foundation to go directly to research and prevention programs. For more information about Lyme disease or to get involved, visit https://www.bayarealyme.org/ or call us at 650-530-2439.

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the U.S., announces the opening of the San Diego collection site of the Bay Area Lyme Foundation's Lyme Disease Biobank, which is the first program to provide researchers with blood and urine samples from people with early Lyme disease from multiple endemic regions across the country.

Related link: https://www.bayarealyme.org/

Twenty-Two States Proclaim March 2020 SUDC Awareness Month for Unexplained Childhood Deaths

ROSELAND, N.J. /ScoopCloud/ -- The Sudden Unexplained Death in Childhood (SUDC) Foundation thanks Alabama, Arkansas, Florida, Georgia, Hawaii, Illinois, Iowa, Louisiana, Massachusetts, Mississippi, New Hampshire, New York, North Carolina, North Dakota, Oklahoma, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, West Virginia for making statewide proclamations declaring March 2020 SUDC Awareness Month.

These are the first states to join a nationwide effort led by the SUDC Foundation to raise awareness of one of the most under-recognized medical tragedies of our time, marking the beginning of a month-long campaign all over the world.

Sudden Unexplained Death in Childhood (SUDC) is a category of death in children over the age of 1 year which remains unexplained after a thorough investigation, including an autopsy. Most often, a seemingly healthy child goes to sleep and never wakes up. Approximately 400 children are lost to SUDC in the United States every year.

"We have made incredible strides as we honor SUDC Awareness Month each March," said Laura Gould Crandall, President and Co-founder of the SUDC Foundation. "Last year, we surpassed serving our 1,000th family since the inception of the SUDC Foundation. While we are sorry for the reason, we are thankful these families were able to connect with our worldwide community and unique range of services. This is a true testament to the SUDC Foundation's tireless outreach and awareness efforts. But we must keep striving to ensure every family who needs us is able to find us and to advocate for research that will help us create a world without SUDC."

The SUDC Foundation will once again mark SUDC Awareness Month by hosting weekly activities for every SUDC supporter to raise awareness of SUDC and remember the children gone far too soon.

To learn more, please visit: https://sudc.org/get-involved/sudc-awareness-month

The SUDC Foundation is advocating for SUDC Awareness Month proclamations in all 50 U.S. states this March. In 2019, 43 U.S. states participated. This nationwide effort began in 2016, inspired by Drew Joseph Boswell and the Boswell family. The Boswell family successfully advocated for the first statewide proclamation declaring March 2015 as SUDC Awareness Month in the State of Louisiana.

To see a full list of previous efforts as well as additional states who have joined, please visit: https://sudc.org/get-involved/legislative-advocacy/sudc-awareness-proclamations

About the SUDC Foundation:

The SUDC Foundation is the only organization worldwide whose purpose is to promote awareness, advocate for research and support those affected by SUDC. The SUDC Foundation provides all services at no cost to families. Learn more: https://sudc.org/

Media Contact:
Stephanie Zarecky
The SUDC Foundation
Tel 973.795.1257
stephanie@sudc.org

*LOGO links for media:
[1] SUDC Logo: https://www.Send2Press.com/300dpi/18-0228s2p-sudc-fdn-300dpi.jpg

[2] Awareness Logo: https://www.Send2Press.com/300dpi/19-0301s2p-SUDC-AwarenessMonth-300dpi.jpg

The Sudden Unexplained Death in Childhood (SUDC) Foundation thanks Alabama, Arkansas, Florida, Georgia, Hawaii, Illinois, Iowa, Louisiana, Massachusetts, Mississippi, New Hampshire, New York, North Carolina, North Dakota, Oklahoma, Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Virginia, West Virginia for making statewide proclamations declaring March 2020 SUDC Awareness Month.

Related link: https://sudc.org/

Susan G. Komen North Jersey Announces Award Honorees Robert C. Garrett, Amparo Aguirre and LAX For The Cure

PARSIPPANY, N.J. /ScoopCloud/ -- Susan G. Komen® North Jersey today announced its Pink Tie Party honorees to be recognized during the March 21st event being held at Ruth's Chris Steak House in Jersey City. For over twenty years, Susan G. Komen North Jersey has helped those who can't pay for treatments, worked to ensure that all people get the care they need, fought for the rights of patients with policy makers and funded breakthroughs in research that saves lives.

This signature event celebrates deserving honorees and raises funds for life-saving North Jersey community programs and national research.

This year's deserving honorees are:

Robert C. Garrett, FACHE, Founders Award Honoree. Bob is CEO of Hackensack Meridian Health and a lifelong advocate working to enhance healthcare service within the community. He is widely recognized for his visionary leadership not only within the field of healthcare, but within the many organizations he supports through his work on advisory boards and boards of directors. Our Founders Award recognizes individuals who have made an impact on healthcare services in the North Jersey community through a lifetime of effort and commitment.

"Susan G. Komen North Jersey's community programs are an example of the very best collaboration in our healthcare community. When nonprofits partner with healthcare systems to deliver initiatives that get into the community with education and prevention programs, the entire community benefits. Hackensack Meridian Health will continue to support the programs that emphasize increasing access to that care," says Bob Garrett.

Amparo Aguirre, Trailblazer Award Honoree. Amparo Aguirre is a Komen-funded

bi-lingual Breast Health Outreach Coordinator at Trinitas Regional Medical Center. Our Trailblazer Award recognizes individuals whose commitment has made an impact on breast cancer awareness, early screening and detection within the North Jersey community.

"I am so honored to receive this award from Komen North Jersey. Saving lives is a privilege that most people don't have the opportunity to enjoy. Providing education and access to screening, particularly in the Latino Community, is my passion and I am grateful for this opportunity that Komen North Jersey provides," says Amparo Aguirre.

LAX for the Cure, Champion Award Honoree. LAX for the Cure is a girls' lacrosse tournament that was founded in 2007 by Jessica Shoulberg, CFO of STEPS Lacrosse LLC. During the summer of 2007, the STEPS Lacrosse club had three mothers fighting breast cancer. The Shoulbergs wanted to help in the fight against the disease and decided to use the growth of girls' lacrosse and the summer tournament circuit as a vehicle. LAX for the Cure was launched to meet the ideals of players, parents, clubs, and college coaches, with the additional goal of raising funds and awareness for the fight against breast cancer.

To date, $3+ million has been raised; an amazing milestone and legacy for such an initiative. The LAX girls are driven competitors who embody the Champion Award that honors a competitive mindset and celebrates the heartfelt work and success of the organization. The girls are celebrated as champions within their sport and champions for the cause of breast cancer.

"Each has contributed immeasurably to our mission and to the fight against breast cancer. We provided them the opportunity to get involved in a life-saving cause and they ran with it. I am so proud of every one of the girls who, through their dedication, are giving hope to the thousands of people, right here, who rely on Susan G. Komen North Jersey to access quality, timely care," says Jessica Shoulberg.

"Our honorees represent the very best in leadership, passion and dedication that gives HOPE to thousands of women and men in North Jersey in need of breast health care or facing a breast cancer diagnosis," says Perla Haltner, Acting Executive Director of Komen North Jersey.

The honorees will be the stars of the evening alongside tasty food, cocktails, gaming and fun. It promises to be a memorable, feel-good night, thanks to the generosity of this year's Pink Tie Party sponsors including: Hackensack Meridian Health, RWJBarnabas, Investors Bank, Dun and Bradstreet, ROI-NJ and TAPinto.net.

About Susan G. Komen®

Susan G. Komen® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Born out of a promise between two sisters, Susan G. Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures.

About Susan G. Komen® and Komen North Jersey

Komen North Jersey is helping fuel research, advocate for patients and support people facing breast cancer locally through a variety of direct patient-centered services and by collaborating with area providers to remove barriers and connect people to needed care across Bergen, Essex, Hudson, Morris, Passaic, Somerset, Sussex, Union and Warren Counties.

For more information, call 908-277-2904 or visit https://komennorthjersey.org/.

Susan G. Komen North Jersey today announced its Pink Tie Party honorees to be recognized during the March 21st event being held at Ruth's Chris Steak House in Jersey City. For over twenty years, Susan G. Komen North Jersey has helped those who can't pay for treatments, worked to ensure that all people get the care they need, fought for the rights of patients with policy makers and funded breakthroughs in research that saves lives.

Related link: https://komennorthjersey.org/

CALNOC Announces the CALNOC Nightingale Research Fund: Raising Nursing’s Voice in Health Services Research

WALNUT CREEK, Calif. /ScoopCloud/ -- CALNOC is pleased to introduce The CALNOC Nightingale Research Fund, an innovative and opportune resource in health services research focused on and administrated by nursing. "We are excited to announce the Research Fund today in honor of Florence Nightingale and in celebration of the Year of the Nurse 2020. This fund will stimulate and support new research and clinical inquiry with emphasis on nursing's contribution," said Dr. Mary E. Foley PhD, RN, FAAN and Chairperson of CALNOC.

"This Fund will provide awards and matching funds to qualified individuals and non-profit institutions in support of clinical inquiry on nursing's contributions to improving clinical care of patients, population health management, staff engagement and satisfaction, and health care operations," added Tony Sung, Chief Executive Officer of CALNOC.

Each year CALNOC will commit substantial support to the fund and announce its research priorities for the current year. Individuals and non-profit institutions are encouraged to apply.

For more information, priorities for funding as well as application process, please go to our website at https://calnoc.org/.

About CALNOC:

Since 1996, CALNOC has been at the forefront of supporting inter professional, nursing focused patient care excellence, creating the first database registry of nursing sensitive quality indicators. As a health services research organization, CALNOC conducts and supports research and clinical inquiry with a focus on nursing's contribution to improving healthcare. Headquartered in Walnut Creek, California, CALNOC is a 501(c)(3) public benefit corporation.

For more information, call 833-225-6621 or visit https://calnoc.org/

CALNOC is pleased to introduce The CALNOC Nightingale Research Fund, an innovative and opportune resource in health services research focused on and administrated by nursing. We are excited to announce the Research Fund today in honor of Florence Nightingale and in celebration of the Year of the Nurse 2020.

Related link: https://calnoc.org/

The OLFACT Test Battery – a Screening Test App for Predicting Alzheimer’s

CINCINNATI, Ohio /ScoopCloud/ -- The OLFACT™ Test Battery, developed by Osmic Enterprises, was initially developed to detect olfactory impairments. Now, it's been adapted as an automated, self-administered screening test to predict Alzheimer's disease/dementia and is being tested by a number of prominent physicians and research laboratories around the United States and in China.

People sense smell through the olfactory nerve and the olfactory system is often one of the earliest sites where the signature neuropathology of Alzheimer's disease is found. The olfactory system is also intricately connected with the hippocampus, a brain structure that plays a major role in the formation of memories. These factors suggest that the sense of smell could be effective in assessing for development of the disease.

The OLFACT™ Test Battery consists of a miniaturized olfactometer (instrument to generate smells) and a tablet-based app which controls presentation of the smells by the olfactometer and administration of the test protocols on the tablet.

The test battery has four standard olfactory function tests: odor identification, memory, discrimination and threshold. The tests are presented in an unbiased manner with computer-accurate consistency concerning timing and smell concentration. The app scores and provides a report of the results and all data is stored in real-time in a central, cloud-based database.

Osmic Enterprises is currently in the process of applying for FDA approval for the test. Once it receives FDA clearance, it can be used with other biomarkers to screen for Alzheimer's/dementia.

In the immediate future, the test can help to select subjects for Alzheimer therapeutics clinical trials. Currently, 10 subjects must be screened to find one acceptable for inclusion into a clinical trial (average cost per enrolled subject, $49,000). The OLFACT™ could potentially increase these odds and help to lower recruitment costs while selecting better suited candidates.

The test has been validated in a number of National Institutes of Health-sponsored clinical trials including one at the Rush Medical Center in Chicago - the Memory and Aging Project. This was a community-based prospective study where normal cognitive adults, 65 and older, were enrolled and underwent annual exams until death. The OLFACT™ Test Battery was added into those annual exams and data was collected for approximately 600 patients for three consecutive years (2010-2012).

Data analysis showed that the results from the OLFACT™ Test Battery can be used to predict the probability of Alzheimer's developing in an individual over a four to 10-year timeframe.

In another study at Harvard, the test battery was shown to accurately identify subjects as being cognitively normal, mildly impaired or having Alzheimer's/dementia. Other clinical trials are underway at Indiana University School of Medicine and Hershey Medical Center/Penn State University.

The OLFACT™ Test Battery is not a diagnostic test, it only predicts the odds that a patient will develop Alzheimer's/dementia.

"The consensus in the field is that since Alzheimer's is a disease with multi-factorial etiologies, there probably will never be a single diagnostic test," Dr. Lloyd Hastings, president and director of research, Osmic Enterprises, says. "It will require a number of screening tests, each probing a different physiological substrate, to obtain a definitive answer and The OLFACT Test Battery is well positioned to be one such test."

By combining cutting-edge technology with sound psychophysical principles, Dr. Hastings says that its innovative tests will become industry standards for assessing the sense of smell in medical clinics, industrial workplaces and research laboratories.

The OLFACT™ Test battery was developed with the aid of SBIR grants funded by the National Institutes of Health/National Institute of Aging.

The product and its data on predicting Alzheimer's will be presented at the Clinical Trials on Alzheimer's disease (CTAD) conference from December 4 through 7 at the Hilton San Diego Bayfront. Dr. Hastings will be available for interviews.

Learn more about the company at: http://www.osmicenterprises.com/

*PHOTO link for media: https://www.Send2Press.com/300dpi/19-1122s2p-OLFACT-Test-Battery-300dpi.jpg
*Photo Caption: OLFACT Test Battery.

The OLFACT™ Test Battery, developed by Osmic Enterprises, was initially developed to detect olfactory impairments. Now, it's been adapted as an automated, self-administered screening test to predict Alzheimer's disease/dementia and is being tested by a number of prominent physicians and research laboratories around the United States and in China.

Related link: http://www.osmicenterprises.com/

SciScore’s Innovative Solution – Pre-clinical Research Gets Tech Boost

SAN DIEGO, Calif. /ScoopCloud/ -- SciScore announces the release of its innovative solution, the first and only working application of its kind, in support of the pre-clinical scientific research community's pursuit of reproducibility and transparency.

"Finding the cure for any medical ailment facing our society, costs money. And, rightly so, the public has great expectation that the money spent on research will advance healthcare," says Anita Bandrowski, a neuroscience researcher at the University of California, San Diego and CEO of SciScore. "This tool makes it easier for researchers to focus on the work-at-hand by indicating when, or if, something was overlooked or omitted in the process of reporting the research in a manuscript."

In January 2016, the National Institute of Health (NIH) introduced new grant review guidelines that focused on four key areas of reproducibility and transparency. This move changed the way in which grants are awarded today. "It remains to be seen in time but it's possible that NIH changed the business of pre-clinical medical research for the better, and for good," Bandrowski said.

In conjunction with NIH, many journals have revised author guidelines to direct researchers to include and emphasize elements required for reproducibility and transparency: PLoS, JBC, eLife, AACR, MBoC, and GSA. SciScore is being piloted by the following publishers: Wiley & Sons, NatureResearch, and eLife.

SciScore provides a score and supporting report that is used by the agency, publisher, or individual author to identify if key areas of reproducibility and transparency are addressed in the manuscript. It uses AI and deep learning technology to calculate a score by looking for evidence of randomization, blinded conduct of experiment, sample size estimation, whether sex is included as a biological characteristic, and cell line authentication or contamination. It also detects any resource ambiguity, like a mislabeled or unidentified cell line.

An author may improve a score by adding information that may be missing or correcting information that is obscure. The manuscript submitted for analysis is removed from the cloud server almost immediately after scoring, keeping information secure and private.

For more information, visit http://sciscore.com/.

About SciScore:

SciScore (SciScore.com) is an application developed by SciCrunch Inc. (scicrunch.com) supported by the Small Business Innovation Research (SBIR) program grants R43OD024432 and R44MH119094.

Media Contact:
Patricia J. Maxwell
Phone: 402.213.0681
Email: info@scicrunch.com

*IMAGE link for media: https://www.Send2Press.com/300dpi/19-1122s2p-sciscore-cloud-300dpi.jpg
*Image caption: SciScore™ - report your science, better.

SciScore announces the release of its innovative solution, the first and only working application of its kind, in support of the pre-clinical scientific research community's pursuit of reproducibility and transparency.

Related link: http://sciscore.com/

iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual Meeting

STONY BROOK, N.Y. /ScoopCloud/ -- iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.

ASH abstracts are now available at https://www.hematology.org/.

Oral Presentation:

Title: First-in-Human Trial of BCMA-CD19 Compound CAR with Remarkable Donor-Specific Antibody Reduction
Session: 721. Abstract Number: 38
Saturday, December 7, 2019: 7:45 a.m.
Valencia BC (W415BC), Level 4 (Orange County Convention Center)
Clinicaltrials.govID: NCT04162353

Poster Presentation:

Title: First-in-Human CD4 CAR Clinical Trial on Peripheral T-Cell Lymphoma
Session: 626. Abstract Number: 2881
Sunday, December 8, 2019, 6 p.m. to 8 p.m.
Hall B, Level 2 (Orange County Convention Center)
Clinicaltrials.govID: NCT04162340

About BCMA-CD19 cCAR therapy

BCMA-CD19 cCAR is a compound Chimeric Antigen Receptor (cCAR) immunotherapy with two distinct functional CAR molecules expressing on a T-cell, directed against the surface proteins BCMA and CD19. The diseases treated by BCMA-CD19 cCAR could include autoimmune disorders, and organ rejection. BCMA is expressed in plasma cells, while CD19 is related to B-cells. BCMA-CD19 cCAR is designed to completely remove antibody-producing "roots", plasma cells and B cells, and then re-set the immune system for treating antibody-mediated autoimmune disorders or organ rejections.

BCMA-CD19 cCAR is also aimed to treat multiple myeloma, a challenging disease due to the heterogeneity of myeloma cells, which renders single-antigen targeting CAR T-cell therapy ineffective. BCMA-CD19 cCAR is proposed to target both bulky myeloma cells expressing BCMA, and myeloma stem cells expressing CD19 to effectively eradicate the disease.

About CD4-specific CAR (CD4 CAR) therapy

CD4-specific CAR with a safety switch is designed to treat peripheral T cell lymphoma as CD4 is uniformly expressed on most mature T cell lymphoma, and transient depletion of CD4 is expected. The diseases treated by CD4 CAR could include peripheral T-cell lymphoma (NOS), Sezary syndrome/cutaneous T-cell lymphoma, angioimmunoblastic T-cell lymphoma, adult T cell lymphoma, T-cell prolymphocytic leukemia, T-cell acute lymphoblastic leukemia/lymphoma and T-cell large granular lymphocytic leukemia. Most of these diseases are difficult to treat, with dismal prognoses. An IND has been approved for iCell Gene Therapeutics to initiate a multi-site clinical trial at Stony Brook University Hospital and University of Louisville.

About iCell Gene Therapeutics

iCell Gene Therapeutics, located in Stony Brook, New York, is a clinical-stage biopharmaceutical company developing first-in-class chimeric antigen receptor engineered cells. Clinical studies on our CARvac, T-cell targeted CARs, Compound CARs, Non-gene edited universal CARs and C-TPS1 (depletion of TREG, blockage of PD-L1 pathways and stimulation of tumor infiltrating lymphocytes) for solid tumors are ongoing in the US and in China.

For more information, please visit http://icellgene.com/

Contact:
Media and Investors
Kevin Pinz
Tel: (631) 538-6218
Kevin.pinz@icellgene.com

iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for hematologic malignancies, solid tumors, organ rejections and autoimmune disorders, announced today that it will give oral and poster presentations related to its BCMA-CD19 cCAR and CD4-specific CAR programs at the 61st American Society of Hematology (ASH) Annual Meeting to be held December 7-10, 2019 in Orlando, Florida.

Related link: http://icellgene.com/

November Is C. diff. Awareness Month

NEW PORT RICHEY, Fla. /ScoopCloud/ -- The C Diff Foundation reemphasizes that the month of November is "C. diff. awareness month" and is being recognized with its partners around the globe again in 2019.

Nancy Caralla, Founding President, Executive Director of the C Diff Foundation, and three-time C. diff. Survivor said, "The month of November was chosen for two reasons. On November 1, 2012 the C Diff Foundation came to fruition. Also, after suffering through the second newly diagnosed CDI with nine-recurrences over a year's time, the month of November was chosen because it was the first month that I received a negative CDI test result without further recurrences."

Caralla further explained that over the past seven years other organizations and survivors, with their families, have joined the C Diff Foundation in "Raising C. diff. Awareness," especially in the month of November originally coined by the C Diff Foundation worldwide.

At the 7th Annual International C. diff. Awareness Conference and Health EXPO held in St. Louis, Missouri on November 6-7, the conference program included Government Agency healthcare professionals and representatives who delivered presentations focused on, but not limited to, Clostridioides difficile. Global organization health care professionals in attendance also recognize November is C. diff. Awareness Month through their presentations, posters, and by introducing products and/or services preventing, treating, diagnosing a CDI and maintaining safer environments in the healthcare community.

C Diff Foundation expresses their gratitude to the numerous state Governors who have recognized C. diff. infections as a leading Healthcare-associated infection by raising awareness during the month of November in their respected states.

According to the Centers for Disease Control and Prevention (CDC), Clostridioides difficile infection (aka C. diff., C. difficile, CDI, CDAD) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile infections cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

Learn more at: https://cdifffoundation.org/

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. EST (http://www.cdiffradio.com/), sponsored by Rebiotix, a Ferring Pharmaceuticals company.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2019

Media Contact:
Kathy Bischoff
C Diff Foundation
kathy@cdifffoundation.org
Office: (727) 205-3922

The C Diff Foundation reemphasizes that the month of November is "C. diff. awareness month" and is being recognized with its partners around the globe again in 2019.

Related link: https://cdifffoundation.org/

National Deaf Chamber of Commerce Names Board of Directors

AUSTIN, Texas /ScoopCloud/ -- The National Deaf Chamber of Commerce (NDCOC), the first organization truly dedicated to advocating and protecting the interests of the Deaf business community, is pleased to announce its Board of Directors, Gina D'Amore, Michael Pimentel, Evan Winegard, and Jared Allebest.

The NDCOC was formed in late 2018 and is in the early stages of enlisting business and programming partners, and these early relationships will be driven by the NDCOC's current board. As part of its next steps, the NDCOC is seeking qualified and enthusiastic additions to its board, individuals who offer unique and diverse strengths and perspectives to help the NDCOC realize its vision.

Gina D'Amore said, "It has been exciting to work with our Board of Directors. They all have unique backgrounds with diverse experiences in the business community that make them an asset to the National Deaf Chamber of Commerce while promoting the needs and interests of the Deaf business community as a whole. We are committed to transparency, inclusivity, and ensuring that the needs of the Deaf business community are met through our new board members."

The NDCOC is currently pursuing partnerships with other local chambers, businesses, and organizations to provide a set of benefits and group services to members of the National Deaf Chamber of Commerce. Partnership goals include provisioning these services in a way that directly supports the needs of Deaf business owners, such as provided resources translated into ASL, or a videophone hotline staffed by Deaf business experts.

About the NDCOC board

Gina D'Amore is the Chief Executive Officer at Mid-Atlantic Interpreting Group, Inc., an SBA 8(a) company. Gina has grown her business to over $4 million, and grew up in both Erie, PA and Houston, Texas in an entrepreneurial environment as she witnessed her families run different businesses. She resides in Maryland, has a son, and also works as a Certified Deaf Interpreter in her goal to provide the best to the Deaf community when it comes to interpreting services.

Michael Pimentel is the Chief Executive Officer of Heart Cruises, LLC, which specializes in cruises, land tours, and all-inclusive resorts all around the world. Michael was also a world-class professional sports photographer for 17+ years and his photos were published in Sports Illustrated and ESPN Magazines. Michael is passionate about international travel and has visited 70+ countries. He is also in the process of launching Blue Wolf Branding, and resides in Union City, California, with his family of six children.

Evan Winegard is the Chief Financial Officer for several companies including CHILMARKeting, a digital advocacy and outreach agency that offers creative and marketing services for business and organizations. Evan was previously the CFO for several multi-million-dollar companies including Maraolo, Biscuits & Bath, Communication Service for the Deaf, and Convo Communications. He also serves as a board member on both the Greater Austin Foundation for the Deaf and the Texas School for the Deaf Foundation.

Jared Allebest is the Chief Executive Officer of Allebest Law Group, a solo practitioner with legal experience in business law, estate planning, discrimination legislation, and advocacy. Jared currently practices law in Arizona, California, and Utah. He previously served as the Chairman for Loop Utah, an ongoing advocacy campaign dedicated to educating those in Utah about the benefits of hearing loop technology.

The goals of the NDCOC are to promote professional opportunities, financial growth, leadership, and legislative awareness that benefits all members of Deaf communities. The National Deaf Chamber of Commerce is in the process of applying for 501(c)(6) status and is not affiliated with any existing organizations. For more information, visit: https://deafchamber.com/

For individuals interested in becoming a Board Member, or for partnership opportunities, please contact the NDCOC board at board@deafchamber.com.

*LOGO link for media: https://www.Send2Press.com/300dpi/19-1101s2p-NDCOC-logo-300dpi.jpg

The National Deaf Chamber of Commerce (NDCOC), the first organization truly dedicated to advocating and protecting the interests of the Deaf business community, is pleased to announce its Board of Directors, Gina D'Amore, Michael Pimentel, Evan Winegard, and Jared Allebest.

Related link: https://deafchamber.com/

Lupus Research Alliance Welcomes New Senior Director of Marketing and Communications

NEW YORK, N.Y. /ScoopCloud/ -- The Lupus Research Alliance (LRA) is pleased to announce that seasoned professional Penny Mitchell has joined the organization as Senior Director of Marketing and Communications. In her new role, Ms. Mitchell will oversee the organization's strategic communications approach to leading lupus research worldwide and the value of participation by all sectors of the lupus community.

Ms. Mitchell comes to the LRA with more than three decades of experience in the healthcare communications field where she has worked at leading agencies such as Fleishman-Hillard, Porter/Novelli and dna/Weber Shandwick. Most recently she served as Executive Vice President, Health Practice Lead for Makovsky, an independent PR firm specializing in regulated industries including healthcare. Prior to that she was U.S. Health Practice Lead for Hill & Knowlton Strategies. She began her career at the Will Rogers Institute, a non-profit pulmonary research organization.

Throughout her career she has driven communications efforts for a range of healthcare clients including non-profit, academic research, pharmaceutical, medtech and consumer health companies. Her experience has involved integrated brand planning, corporate reputation management, issues/crisis management, media strategy, data communications, public/private partnerships and advocacy relations.

Her experience in autoimmune diseases is particularly strong having launched several highly effective communications campaigns for pharmaceutical companies working in lupus as well as psoriasis, diabetes, multiple sclerosis, Crohn's disease and thyroid disorders.

"We are tremendously excited about adding Penny to our team," commented LRA Executive Director Andrea O'Neill. "In addition to her breadth of knowledge, Penny brings enormous creativity, strategic thinking and scientific acumen as well as dedication to empowering people with challenging medical issues."

"The Lupus Research Alliance has long been at the center of the lupus community committed to funding research, forging collaboration and finding a cure for this complex, highly-individualized autoimmune disease," said Ms. Mitchell. "I am delighted to join forces with this extraordinary group to bring greater attention to its groundbreaking research efforts, the needs of the community and ultimately, improving the lives of people with lupus."

About Lupus:

Lupus is a chronic, complex autoimmune disease that affects millions of people worldwide. More than 90 percent of people with lupus are women; lupus most often strikes during the childbearing years of 15-45. African Americans, Latinx, Asians and Native Americans are two to three times at greater risk than Caucasians. In lupus, the immune system, which is designed to protect against infection, creates antibodies that can attack any part of the body including the kidneys, brain, heart, lungs, blood, skin, and joints.

About the Lupus Research Alliance:

The Lupus Research Alliance aims to transform treatment while advancing toward a cure by funding the most innovative lupus research in the world. The organization's stringent peer review grant process fosters diverse scientific talent who are driving discovery toward better diagnostics, improved treatments and ultimately a cure for lupus. Because the Lupus Research Alliance's Board of Directors fund all administrative and fundraising costs, 100 percent of all donations go to support lupus research programs. Learn more at: https://www.lupusresearch.org/

*PHOTO link for media: https://www.Send2Press.com/300dpi/19-1116s2p-LRA-Penny-Mitchell-300dpi.jpg

The Lupus Research Alliance (LRA) is pleased to announce that seasoned professional Penny Mitchell has joined the organization as Senior Director of Marketing and Communications. In her new role, Ms. Mitchell will oversee the organization's strategic communications approach to leading lupus research worldwide and the value of participation by all sectors of the lupus community.

Related link: https://www.lupusresearch.org/

C Diff Foundation’s Junior Infection Fighters Program Takes Action against Harmful Germs One Community at a Time Worldwide

NEW PORT RICHEY, Fla. /ScoopCloud/ -- C Diff Foundation announced today that the inaugural C Diff Foundation Junior Infection Fighter Program was introduced to families and their children/teens in Chester County, Pennsylvania on October 12, 2019.

Dayle Skelly, Director of the Junior Infection Fighter Program and C. diff. Survivor said, "There shouldn't be an age limit for raising awareness of infection prevention. Children are our future and take forth the torch of knowledge to be shared with everyone in each community."

The volunteer program has been developed for children/teens with the participation and support of their parents/legal guardian and supervision of C Diff Foundation adult volunteers. C Diff Foundation's Junior Infection Fighters Program mission: "To educate and advocate for infection prevention with the children and teens and to inspire their social, academic, personal, and health care knowledge and partner with parents who share the same mission to prepare them to be members of ever changing global health care in societies worldwide."

C Diff Foundation's Junior Infection Fighter guidelines have been brought to fruition, under the direction of a leading infection preventionist, Maureen Spencer, RN, M.Ed., CIC.

Ms. Spencer who has been an Infection Preventionist for over 30 years and board certified in infection control (CIC). As one of the early pioneers in infection control, she was awarded the APIC National Carole DeMille Award in 1990 and was selected as one of the APIC Heroes of Infection Prevention in 2007 for her work in establishing a MRSA and Staph aureus Elimination Program at New England Baptist Hospital, an Orthopedic Center of Excellence in Boston. The ground breaking work was published in the Journal of Bone and Joint Surgery

All volunteer attendees enjoyed spending time learning more about practicing healthy habits combined with infection prevention information during the inaugural community event.

"We work together to carve new paths in the multi-faceted patient and family programs offered by C Diff Foundation. Together we build awareness and advocate for C. diff. infection prevention, treatments, clinical trials, antibiotic-resistance, and environmental safety worldwide. We are truly grateful to the dedicated members taking the C Diff Foundation's mission to greater levels changing lives, and saving lives across the globe," said Nancy C. Caralla, Founding President, C Diff Foundation.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. ET (www.cdiffradio.com), sponsored by Rebiotix, a Ferring Pharmaceuticals company.

Learn more at: http://cdifffoundation.org

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Twitter @cdiffFoundation @Cdiff2019

Media Contact:
Dayle Skelly
Director Junior Infection Fighters Program
C Diff Foundation
info@cdifffoundation.org
Office: (727) 205-3922

*IMAGE link for media: https://www.Send2Press.com/300dpi/19-1015s2p-CdiffJuniorInfectionFighters-300dpi.jpg

###
Costs associated with dissemination of this news announcement were donated to the C Diff Foundation by NEOTROPE®, a California-based marketing company.

C Diff Foundation announced today that the inaugural C Diff Foundation Junior Infection Fighter Program was introduced to families and their children/teens in Chester County, Pennsylvania on October 12, 2019.

Related link: https://cdifffoundation.org/

C Diff Foundation Raises Clostridioides difficile Awareness in St. Louis on Nov. 6-7 at 7th Annual International Conference and Health EXPO

ST. LOUIS, Mo. /ScoopCloud/ -- C Diff Foundation announced today that the 7th Annual International C. diff. Conference and Health EXPO is honored to welcome over 30 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies.

Presenters will deliver data and discuss critical information on a leading Healthcare-Associated Infection (HAI), Clostridioides difficile with global healthcare-associated issues on November 6 - 7, 2019 at the DoubleTree by Hilton Westport Hotel, 1973 Craigshire Road, St. Louis, MO 63146; Telephone: +1 (314) 434-0100.

To learn more about this extraordinary conference, guest speakers, and the diverse topics being presented visit: https://cdifffoundation.org/2019-guest-speakers/

All attendees will have the highest levels of peer networking and learning opportunity at the Conference and Health EXPO.

C Diff Foundation expresses their gratitude to Pfizer for being the conference Diamond Sponsor. Pfizer is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide. This activity has been supported by an independent patient advocacy Grant from Merck & Co., Inc., and the members of the C Diff Foundation are truly grateful.

Attendee Paul Feuerstadt MD, FACG, AGAF stated, "The annual C Diff Foundation conference and health expo is an essential conference for me to attend, given the comprehensive presentations about epidemiology, disease state, patient experience, infection control and innovations with treatment of C. difficile. The level of detail and data presented has a wonderful balance that is understandable for someone casually interested in the infection but also exceeds the expectations for those who are experts in the field wanting to share and exchange ideas with other thought leaders."

According to the Centers for Disease Control and Prevention (CDC), Clostridioides difficile infection (aka C. diff., C. difficile, CDI, CDAD) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile infections cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals is dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, AMR, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesday's at 1 p.m. EST (www.cdiffradio.com) sponsored by Rebiotix, a Ferring Pharmaceuticals company.

Learn more at: https://cdifffoundation.org/.

Follow C Diff Foundation on LinkedIn, Twitter, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2019

Media Contact:
Angelo Ortiz
C Diff Foundation
angelo.ortiz@cdifffoundation.org
Office: (727) 205-3922

*IMAGE link for media: https://www.Send2Press.com/300dpi/19-1015s2p-cdiff-nov-expo-300dpi.jpg

C Diff Foundation announced today that the 7th Annual International C. diff. Conference and Health EXPO is honored to welcome over 30 international topic-experts dedicated in disciplines of healthcare, pharma, biotech, academia, and Government agencies. November 6 - 7, 2019 at the DoubleTree by Hilton Westport Hotel.

Related link: https://cdifffoundation.org/

Fifteen Neurotechnology Startups to Present at the 2019 Neurotech Leaders Forum in San Francisco

SAN FRANCISCO, Calif. /ScoopCloud/ -- Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that 15 promising neurotechnology startups and early-stage firms will present at the 2019 Neurotech Leaders Forum in San Francisco, November 4-5. The 19th annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.

Josh Makower, general partner at VC firm New Enterprise Associates, will keynote on the first day of the conference. Makower is cofounder of the Stanford Byers Biodesign Center and also founder and executive chairman of ExploraMed, a medical device incubator that has created eight companies over the past 20 years.

Robert Knight, professor of psychology and neuroscience and director emeritus of the Helen Wills Neuroscience Institute at UC Berkeley, will deliver the keynote on the second day of the event. Knight is the recipient of the Jacob Javits Neuroscience Investigator Award from the National Institutes of Health for distinguished contributions to neurological research. He is also the chief science advisor of Neurofocus Inc., the consumer neurotech spinoff company acquired by market research firm Nielsen.

The agenda for this year's event includes panel discussions on a number of topics, including sessions devoted to clinical trials, securing funding, the new competitive landscape in neuromodulation, closed-loop stimulation, and neurorehabilitation. New this year is an editorial roundtable featuring Neurotech Reports editors James Cavuoto, Jennifer French, Jeremy Koff, and Margot Puerta, who will each offer their perspectives on issues confronting the industry.

Among the companies presenting this year are Saluda Medical, Nia Therapeutics, Neuroelectrics, Humm, Evoke Neuroscience, Neural Dynamics Technologies, Spark Biomedical, Thermaquil, Humm, Neuraura, CareWear, Rune Labs, Neural Signals, and BIOS.

The Platinum Sponsor at this year's event is Cirtec Medical. Micro Systems Technology is the Gold Sponsor. Maynard Cooper and Integer are Silver Sponsors, and RBrooks Group, Senso Medical, and the Cleveland FES Center are Bronze Sponsors.

"We're excited about the lineup of speakers at this year's event," said James Cavuoto, editor and publisher at Neurotech Reports. "As in the past, attendees will have many opportunities to interact with potential partners and colleagues."

For more information on attending or sponsoring, contact Neurotech Reports at 415 546 1259 or visit this link: http://neurotechreports.com/pages/leadersforum.html.

Neurotech Reports, the publisher of the Neurotech Business Report newsletter, announced that 15 promising neurotechnology startups and early-stage firms will present at the 2019 Neurotech Leaders Forum in San Francisco, November 4-5. The 19th annual event-the most established in the industry-will also feature presentations and panel discussions on important issues confronting the neurotechnology industry.

Related link: http://www.neurotechreports.com/

Walk with Us to Cure Lupus, New York – There’s Strength in Our Strides!

NEW YORK, N.Y. /ScoopCloud/ -- Join New York's lupus community and the Lupus Research Alliance (LRA) Saturday, October 12 to Walk with Us to Cure Lupus at the Intrepid Sea, Air & Space Museum in Manhattan.

Walk with Us to Cure Lupus is the LRA's signature national program that unites communities across the country to achieve one goal - to raise the much-needed funds to improve care and find the cure.

In lupus, the immune system, which should protect against infection, instead creates antibodies that can attack any part of the body. More than 90% of the millions of people worldwide who live with lupus are women. African Americans, Latinx, Asians and Native Americans are two to three times at greater risk than Caucasians.

This day is set for a true celebration. Before and after the Walk, participants can take part in Tie Dying tee shirts, face painting, Team photos, and signing the annual Hope Begins Here banner displayed in the LRA national office in NYC. Free breakfast, snacks and a 25% discount at Coldstone Creamery add to the fun for all ages.

The Walk route is about 3.1 miles around the Intrepid on Pier 86 at West 46th Street. Walkers are encouraged to go at their own pace and cover their own distance; it is not necessary to complete the route. For more information about the NYC Walk, contact Elizabeth Vega-Eng at lupuswalknyc@lupusresearch.org or 646.884.6043.

"Thousands are walking across the United States to raise awareness and funds for lupus research," comments Kenneth M. Farber, President and CEO of the Lupus Research Alliance. "Through the efforts of communities like New York, this program has contributed millions to be invested in the most innovative and promising research that has led to every pivotal advance in lupus to date."

The lupus community thanks Walk sponsors for their ongoing support and commitment: Empire Blue Cross Blue Shield, Hospital for Special Surgery, NY Jets, Northwell Health, GSK, Us in Lupus, First Data, Cantor Fitzgerald, WCBS/WLNY, iHeart Radio, Aurinia.

Visit http://www.lupusresearch.org/ to learn more about the LRA and scientific breakthroughs that are transforming lupus treatment.

Get the latest news, share your experiences and support others on LRA's Community Forum, Twitter, Instagram and Facebook.

About the Lupus Research Alliance

The Lupus Research Alliance aims to transform treatment while advancing toward a cure by funding the most innovative lupus research in the world. Because the Lupus Research Alliance's Board of Directors fund all administrative and fundraising costs, 100% of all donations goes to support lupus research programs.

Join New York's lupus community and the Lupus Research Alliance (LRA) Saturday, October 12 to Walk with Us to Cure Lupus at the Intrepid Sea, Air & Space Museum in Manhattan.

Related link: https://www.lupusresearch.org/

Susan G. Komen North Jersey’s MORE THAN PINK Wellness Expo, Presented by Aetna, Comes to Jersey City, NJ Sunday, October 6

JERSEY CITY, N.J. /ScoopCloud/ -- Susan G. Komen North Jersey, will be holding its MORE THAN PINK Wellness Expo on Sunday, October 6, 2019 at the Harborside Atrium in Jersey City from 12 p.m. - 4 p.m. This interactive health and wellness expo will offer attendees convenient access to education and critical health screening services, health/wellness exhibits, fitness/nutrition demonstrations, survivor support, a senior pavilion, medical information and genetic testing.

This year's event also features award-winning breast surgeon, breast cancer survivor, and Jersey City native, Julia M. DiGioia, M.D., F.A.C.S. As the event chairperson, Dr. DiGioia embodies the Wellness Expo mission to bring health and wellness solutions to our community.

The MORE THAN PINK Wellness Expo is free to attend.
Health screenings available include: clinical breast exams, mammograms, blood pressure, blood sugar, cholesterol, dental, PSA, HIV, cognitive screening, and a senior pavilion. Mammograms are available to all insured or uninsured participants by calling Hoboken Family Planning at 201-963-0300 in advance to reserve your Expo appointment. There are limited spots available.

"Awareness and knowledge are a person's strongest ally when it comes to battling illness," said Perla Haltner, Acting Executive Director of the Susan G Komen North Jersey. "We urge everyone in the North Jersey area to join us for this Wellness Expo and take advantage of the terrific services and information available there."

Since its inception, the North Jersey affiliate of the Susan G. Komen organization has focused on community involvement to enhance, support, and provide area breast cancer patients access to critical services. Susan G. Komen North Jersey relies on the support and collaboration of its dedicated community partners to raise awareness of breast cancer detection, support services and educational services we provide in the 9-county Northern New Jersey area.

The Harborside Atrium event location is provided by host Mack-Cali and Expo visitors can easily access the Jersey City location via a NY Waterway ferry. The NY Waterway is the event's Community Impact Sponsor.

For this event Susan G. Komen North Jersey is teaming up with an array of sponsors and partners to offer a Wellness Expo where anyone can access all types of health professionals and screenings to begin their journey to better health.

Expo sponsors include, Atlantic Health Systems, RWJ Barnabas Health, Pfizer Oncology, Myriad Women's Health, Alliance Community Healthcare, Inc., Hoboken Family Planning, Montclair Radiology, Horizon, Hudson County Family Planning, NJCEED, Hackensack Meridian Health, Jersey City Department of Health & Human Services and City of Jersey City.

MORE THAN PINK WELLNESS EXPO Presented by Aetna
Sunday, October 6, 2019; 12 - 4 p.m.
HARBORSIDE ATRIUM
210 Hudson Street, Jersey City, NJ 07302

Susan G. Komen North Jersey holds a number of events each year. For more information about the Wellness Expo visit: https://komennorthjersey.org/expo/

About Susan G. Komen(R)

Susan G. Komen(R) is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Born out of a promise between two sisters, Susan G. Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures.

About Susan G. Komen North Jersey(R)

Komen North Jersey is helping fuel research, advocate for patients and support people facing breast cancer locally through a variety of direct patient-centered services and by collaborating with area providers to remove barriers and connect people to needed care across Bergen, Essex, Hudson, Morris, Passaic, Somerset, Sussex, Union and Warren Counties. For more information, call 908-277-2904 or visit https://komennorthjersey.org/.

Media Contact:
Jana McDonough
Komen North Jersey
1-516-673-6322
media@komennorthjersey.org

Susan G. Komen North Jersey, will be holding its MORE THAN PINK Wellness Expo on Sunday, October 6, 2019 at the Harborside Atrium in Jersey City from 12 p.m. - 4 p.m. This interactive health and wellness expo will offer attendees convenient access to education and critical health screening services, health/wellness exhibits, fitness/nutrition demonstrations, survivor support, a senior pavilion, medical information and genetic testing.

Related link: https://komennorthjersey.org/

Susan G. Komen North Jersey Honors Arthur E. Imperatore with Inaugural Community Impact Award

WEEHAWKEN, N.J. /ScoopCloud/ -- Susan G. Komen North Jersey announced today it presented its inaugural Community Impact Award to Arthur Imperatore Sr., Founder and resident of NY Waterway, the largest commuter ferry fleet in New York Harbor, providing commuter ferry and bus services between New Jersey and Manhattan.

The award has been specially created to recognize companies and individuals who have made a lasting contribution to the local cancer fighting efforts that Susan G. Komen North Jersey facilitates. The award was presented on September 19 at a ceremony at NY Waterway corporate headquarters in Weehawken, N.J.

Since its inception, the North Jersey affiliate of the Susan G. Komen organization has always relied on community involvement and engagement to enhance, support, and provide area breast cancer patients access to critical services. Through the Community Impact Award, the nonprofit hopes to honor and recognize the people and organizations that have helped Susan G. Komen North Jersey deliver on its mission of achieving significant community impact through local partnerships and collaboration.

"Arthur has been the example of community partners for Komen North Jersey. Under his leadership, NY Waterway has extended valuable resources to help get our message out to their customers and rally support for our local initiatives," said Perla Haltner, Acting Executive Director of Susan G. Komen North Jersey. "As an integral part of the Komen team, Arthur and NY Waterway have introduced us to other community leaders who've been champions when it comes to helping us raise awareness of breast cancer detection, support services and educational services we provide in the 9-county Northern New Jersey area."

"As a family business, NY Waterway has supported the communities and people of Northern New Jersey for over 70 years," said award recipient and NY Waterway's Founder, Arthur E. Imperatore. "I'm honored to receive this recognition and can't wait to promote more of the great work Susan G. Komen North Jersey is doing in this region."

Susan G. Komen North Jersey holds a number of events each year, including their upcoming Susan G. Komen North Jersey FREE Wellness Expo which will be held Sunday, October 6th at the Harborside Atrium in Jersey City. The Expo will offer a number of free screenings including: clinical breast exams, mammograms, blood pressure, glucose, cholesterol, dental, PSA, HIV and more. NY Waterway is an official Community Impact sponsor of this event.

For more information about the Wellness Expo visit: https://komennorthjersey.org/expo/

About NY Waterway

NY Waterway has the largest commuter ferry fleet in New York Harbor, but it is still a family business with all the personal attention to service and amenities that it had when it started with just one boat in 1986.

NY Waterway operates the largest privately-owned commuter ferry service in the U.S., carrying more than 32,000 passenger trips per day - 10 million trips per year - on 35 boats serving 23 routes between New Jersey and Manhattan, and between Rockland and Westchester counties, and between Orange and Dutchess counties. A fleet of 70 NY Waterway buses provide a free, seamless commute between ferry terminals in New York and New Jersey and inland locations.

About Susan G. Komen(R)

Susan G. Komen(R) is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Born out of a promise between two sisters, Susan G. Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures.

About Susan G. Komen North Jersey(R)

Komen North Jersey is helping fuel research, advocate for patients and support people facing breast cancer locally through a variety of direct patient-centered services and by collaborating with area providers to remove barriers and connect people to needed care across Bergen, Essex, Hudson, Morris, Passaic, Somerset, Sussex, Union and Warren Counties.

For more information, call 908-277-2904 or visit http://komennorthjersey.org/.

Media Contact:
Jana McDonough
Komen North Jersey
1-516-673-6322
media@komennorthjersey.org

Susan G. Komen North Jersey announced today it presented its inaugural Community Impact Award to Arthur Imperatore Sr., Founder and resident of NY Waterway, the largest commuter ferry fleet in New York Harbor, providing commuter ferry and bus services between New Jersey and Manhattan.

Related link: https://komennorthjersey.org/

Fluid Metering Appoints REVODIX as Sole Distributor Partner in South Korea

SYOSSET, N.Y. /ScoopCloud/ -- Fluid Metering, Inc., a pioneer in design and manufacturing of high-performance fluid handling solutions, is pleased to announce a new distribution agreement with REVODIX Inc. This partnership leverages the combined strength of Fluid Metering's ultra-precise fluid control products with REVODIX's dedicated focus and distribution expertise in the life sciences market - supporting Korea's increased emphasis on research and development a key driver in bolstering its global competitiveness.

REVODIX Inc., headquartered in Gyeonggi-do, was founded in 1995 and is the only company in Korea that handles all liquid transfer products from consumables to equipment. REVODIX is not only selling products, they also, provide repair, consulting and technical support services to Korean research institutes and related companies.

"We are proud to be part of the Fluid Metering family and look forward to introducing a high-class rotary piston pump - valveless metering pump - to the Korean market," said Mr. Jong-Hoon Shin, CEO at REVODIX Inc.

"We couldn't be happier than having the REVODIX team promoting Fluid Metering to the Korean market. The REVODIX team of extremely knowledgeable fluidic sales engineers have the skill and will we look for in a channel partner," said Mr. Robert Morin, Vice President, Commercial Operations at Fluid Metering, Inc.

About Fluid Metering, Inc.

Fluid Metering, Inc. pioneered the first patented valveless rotating and reciprocating piston metering pump concept delivering pumping excellence and precise fluid control for Laboratory, Industrial, Process and OEM applications. Fluid Metering's Engineering Team incorporates 60 years of OEM design experience to meet specific customer and application requirements with Accuracy, Precision & Reliability!

Fluid Metering, Inc., was founded in 1959 and is headquartered in Syosset, New York.

Learn more at: https://www.fluidmetering.com/

Media Contact:
Denise Sternbach
Phone: 516-922-6050 xt.113
Denise.Sternbach@fmipump.com

*LOGO link for media: https://www.Send2Press.com/300dpi/19-0916s2p-fluid-metering-300dpi.jpg

Follow on social at:
Twitter: https://twitter.com/fluidmetering
LinkedIn: https://www.linkedin.com/company/fluid-metering-inc-/

Twitter: @fluidmetering #fmikoreanpartnership #REVODIX #fluidcontrolproducts

Fluid Metering, Inc., a pioneer in design and manufacturing of high-performance fluid handling solutions, is pleased to announce a new distribution agreement with REVODIX Inc. This partnership leverages the combined strength of Fluid Metering's ultra-precise fluid control products with REVODIX's dedicated focus and distribution expertise.

Related link: https://www.fluidmetering.com/

C.diff. International Conference and Health EXPO Will Deliver Up-to-date Clostridioides difficile Data + More Nov. 6-7 In St. Louis

ST. LOUIS, Mo. /ScoopCloud/ -- The C Diff Foundation is honored to welcome 30+ international leading topic experts from hospitals, pharma, biotech, academia, and Government agencies to deliver and discuss critical information on global healthcare-associated issues.

To learn more about this extraordinary conference, agenda and guest speakers: https://cdifffoundation.org/2019-guest-speakers/

Clinical professionals will gather for two days to present up-to-date data to expand on the existing knowledge and raise awareness of the urgency focused on, but not limited to, Clostridioides difficile (formally known as Clostridium difficile) infection (CDI) Prevention, Treatments, Research, Diagnostics, Clinical trials, and Environmental Safety.

There will also be presentations exclusively concentrated on Infection prevention, Fecal microbiota restoration and transplants for adults, a Panel of C. diff. infection Survivors; a patient's perspective, Microbiome research, Scientific posters and poster presentations, Antibiotic stewardship, Antimicrobial resistance, and a Healthcare EXPO component.

All attendees will have the highest levels of peer networking and learning opportunity at the Conference and Health EXPO. The conference program builds in time for face-to-face interaction between attending executives, corporate representatives and industry experts exhibiting.

C Diff Foundation expresses their gratitude to Pfizer for being the conference Diamond Sponsor. Pfizer is appreciated for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide.

Attendee Linda Davis, RN, Patient Triage Specialist, said about the 2018 conference, "It's an excellent opportunity to have the ability to network with fellow-healthcare professionals from around the world. Each conference I have attended presents the opportunity to acquire knowledge with like-minded professionals striving to make a difference in the health care community. Attendees obtain the most innovative cutting-edge research and developments fighting today's complex world of healthcare-associated infections."

According to the Centers for Disease Control and Prevention (CDC), Clostridioides difficile infection (aka C.diff., C. difficile, CDI, CDAD) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile infections cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

About The C Diff Foundation:

C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for Clostridioides difficile infection (CDI) prevention, treatments, clinical trials, and environmental safety worldwide. Listen to "C.diff. Spores and More" Tuesdays at 1 p.m. ET (www.cdiffradio.com), sponsored by Rebiotix, a Ferring Pharmaceuticals company, providing leading up-to-date information on topics that are aligned and connect with their organization's mission and more.

Learn more: https://cdifffoundation.org/

Follow C Diff Foundation on LinkedIn, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2019

Media Contact:
Angelo Ortiz
C Diff Foundation
angelo.ortiz@cdifffoundation.org
Office: (727) 205-3922

The C Diff Foundation is honored to welcome 30+ international leading topic experts from hospitals, pharma, biotech, academia, and Government agencies to deliver and discuss critical information on global healthcare-associated issues.

Related link: https://cdifffoundation.org/

Founder of Stillbrave Childhood Cancer Foundation to Run 206-Mile Ultra-Marathon on Mount St. Helens Volcano

BURKE, Va. /ScoopCloud/ -- Stillbrave Childhood Cancer Foundation announced that its founder and director, "Tattoo Tom" Mitchell is on a mission to raise $500,000 to support children with cancer and their families. From August 9 through 13, he will return to Mount St. Helens to make his fourth attempt at what's been called "the most challenging endurance race in North America" - the Bigfoot 200.

The race is 206.5 miles and he'll be joined by Loren Jewell, a childhood cancer survivor and firefighter who beat the odds after being told upon diagnosis that she might never walk again. Pacing Mitchell and Jewell is Katie Healy, a pediatric oncology nurse who cared for not only Jewell, but also Mitchell's daughter, Shayla, while she was undergoing cancer treatment.

The Bigfoot 200 is Stillbrave's largest fundraising effort of the year and they hope to meet their fundraising goal through sponsorships and direct donations. Each mile is dedicated to a different child impacted by cancer and funds are raised in their honor. Mitchell and Jewell will carry pictures of these children and will acknowledge them at each mile.

After Mitchell's daughter, Shayla, lost her hard-fought battle with childhood cancer in 2009, he founded Stillbrave Childhood Cancer Foundation. He's dedicated his life to helping the families of children battling cancer in any way possible.

Mitchell's ability to console the inconsolable is an invaluable asset within the confines of a hospital room. Humor and compassion, and first-hand knowledge, are almost impossible to quantify and cannot be delivered in a gift card or care package.

"Shayla died in 2009. I'm not running this for my daughter; I'm running it for yours," Mitchell says.

About Stillbrave Childhood Cancer Foundation:

Stillbrave Childhood Cancer Foundation is a 501(c)(3) non-profit organization that provides non-medical support to children with cancer and their families. It helps them financially and emotionally, on a case-by-case basis, as they struggle with the toughest battle of their lives. Learn more at: https://www.stillbrave.org/

To sponsor a mile of the race in honor of a child impacted by cancer, or to make a donation of any kind, visit https://run.stillbrave.org/ or contact Mitchell at: bigfoot4@stillbrave.org.

Facebook:
- https://www.facebook.com/Stillbrave/
- https://www.facebook.com/tattootom1

*PHOTO link for media: Send2Press.com/300dpi/19-0701s2p-tom-mitchell-300dpi.jpg
*Photo caption: Tom Mitchell will set out to run his fourth attempt at a 200-mile ultra-marathon race to benefit children with cancer and their families on August 9 - 13, 2019.

Stillbrave Childhood Cancer Foundation announced that its founder and director, "Tattoo Tom" Mitchell is on a mission to raise $500,000 to support children with cancer and their families. From August 9 through 13, he will return to Mount St. Helens to make his fourth attempt at what's been called "the most challenging endurance race in North America" - the Bigfoot 200.

Related link: https://www.stillbrave.org/

2019 Lupus Insight Prize Awarded to Dr. Ignacio Sanz: Recognizes Studies of Harmful Immune Cells in Lupus

BOSTON, Mass. /ScoopCloud/ -- The Lupus Research Alliance has awarded its 2019 Lupus Insight Prize to Ignacio Sanz, MD, for discovering that certain little-understood immune system cells are a major source of the harmful proteins that promote lupus symptoms. His work could spark new treatments for the disease and help doctors determine which patients could benefit from current drugs. Dr. Sanz is a Mason Lowance Professor of Medicine and Pediatrics and Chief of the Division of Rheumatology at Emory University School of Medicine in Atlanta, Georgia.

The award was announced June 19 at FOCIS 2019, the 19th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS). The $100,000 award recognizes a major, novel insight and/or discovery with the promise of changing thinking about lupus as well as a high probability of generating further advances in the diagnosis and treatment of the disease.

"Dr. Sanz has already made vital contributions to understanding the role of B cells in lupus," said Kenneth M. Farber, President and CEO, Lupus Research Alliance. "We very much look forward to his next advances afforded by our Lupus Insight Prize."

Dr. Sanz's discoveries were a breakthrough for understanding how certain B cells, a type of immune cell, promote lupus. B cells are key for the disease. Their normal job is to produce proteins called antibodies that protect against bacteria and viruses. But in lupus, B cells release antibodies that trigger damage to patients' own tissues. Researchers have known that some B cells must mature in specialized parts of the lymph nodes or spleen before they can make these destructive antibodies.

Dr. Sanz showed that many damaging B cells follow a different route and identified the molecular mechanisms that underpin this B cell activation pathway. He and his team were the first to apply a comprehensive characterization of these cells using cutting-edge techniques such as multidimensional flow cytometry analysis of DNA in lupus patients. They found that this group of B cells was prevalent in patients who were undergoing lupus flares, particularly African-Americans. Dr. Sanz and his colleagues also found that, in contrast to healthy subjects, the lupus B cells were ready to transform into cells that produce harmful antibodies, even in patients without active disease.

"I thank the Lupus Research Alliance for recognizing my work, and I am eager to pursue further research with the potential for improving patient treatment," said Dr. Sanz.

Researchers may be able to build on Dr. Sanz' discoveries to develop new drugs that could reduce patients' risk and severity of disease flares. The results could also help doctors identify subsets of lupus patients that are more likely to benefit from therapies that destroy B cells using existing drugs. In addition, the cellular and molecular make-up of the abnormal lupus B cells should help identify new therapeutic targets.

About Lupus

Lupus is a chronic, complex autoimmune disease that affects millions of people worldwide. More than 90% of people with lupus are women; lupus most often strikes during the childbearing years of 15-45. African Americans, Latin Americans, Asians and Native Americans are two to three times at greater risk than Caucasians. In lupus, the immune system, which is designed to protect against infection, creates antibodies that can attack any part of the body including the kidneys, brain, heart, lungs, blood, skin, and joints.

About the Lupus Research Alliance

The Lupus Research Alliance aims to transform treatment while advancing toward a cure by funding the most innovative lupus research in the world. The organization's stringent peer review grant process fosters diverse scientific talent who are driving discovery toward better diagnostics, improved treatments and ultimately a cure for lupus. Because the Lupus Research Alliance's Board of Directors funds all administrative and fundraising costs, 100% of all donations goes to support lupus research programs.

Learn more at: https://www.lupusresearch.org/

The Lupus Research Alliance has awarded its 2019 Lupus Insight Prize to Ignacio Sanz, MD, for discovering that certain little-understood immune system cells are a major source of the harmful proteins that promote lupus symptoms. His work could spark new treatments for the disease and help doctors determine which patients could benefit from current drugs.

Related link: https://www.lupusresearch.org/

World Renowned C Diff Foundation Announces First Ever Appointment of Paul Feuerstadt, M.D. as Director of Medical Education

NEW PORT RICHEY, Fla. /ScoopCloud/ -- C Diff Foundation, a one hundred percent volunteer, world renowned 501(c)(3) not-for-profit organization, has appointed nationally renowned Gastroenterologist, Dr. Paul Feuerstadt as its first Director of Medical Education.

Dr. Feuerstadt said, "It is my honor to accept this position. I have been involved with the C Diff Foundation over the last 4.5 years and I look forward to assisting in the continued growth of the organization and ensuring that forward progress, awareness and education increases under my tenure. I look forward to working with the board and volunteers to increase awareness and funding across the country and around the world to highlight this disease through in person events, social media, and in the press."

Dr. Feuerstadt has spent his career refining his practice and expertise in C. difficile. He is dedicated to educating the public through his work with this organization.

Additionally, he plans to offer free patient and provider education through the launch of his new educational website, https://www.everythingcdifficile.com/. The goal of the site is to provide education through short videos with relevant clinical information for educational purposes. The site provides concise 3-5 minute lectures covering core topics, recent publications and major conferences about C. difficile infection to educate both patients and providers.

Nancy C. Caralla, Founding President, C Diff Foundation, commented: "Dr. Feuerstadt is a pre-eminent doctor in this space. His dedication and donation of his time and energy to this worthy cause has helped so many patients to date. We look forward to his enhanced leadership and knowledge as the organization grows and strengthens through our advocacy in the C.diff. community. Dr. Feuerstadt's new role as Director of Medical Education will provide an additional avenue of support to patients, families, and caregivers through his educational media available on EverythingCdifficile.com. We are grateful for Dr. Feuerstadt's time and dedication as we continue fighting this debilitating disease worldwide."

About C Diff Foundation:

The C Diff Foundation's mission is dedicated to reaching out to communities from villages to cities, to medical practitioners, medical students, C. diff. survivors, caregivers, and the patients combating a C. difficile infection (CDI) while providing the general public important information on prevention, treatments available, clinical trials in progress, and EPA registered products available for environmental safety.

The C Diff Foundation continues moving forward setting up outreach centers and building positive networks with the C Diff Foundation Volunteer Health Advocates aiding in "Raising C.diff. Awareness" worldwide.

Learn more: https://cdifffoundation.org/

About Dr. Paul Feuerstadt:

His areas of interest Clostridioides difficile infection and ischemic diseases of the gut and in these areas he has presented his research extensively, authored and co-authored many manuscripts, textbook chapters and online modules. Another passion of Dr. Feuerstadt's is teaching, frequently giving lectures locally, regionally and nationally. He holds a clinical appointment as an Assistant Clinical Professor of Medicine at the Yale University School of Medicine and is a full time attending physician at the Gastroenterology Center of Connecticut seeing patients with a broad spectrum of clinical gastroenterological diseases.

Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan for medical school and completed his residency in internal medicine at New York Presbyterian Hospital/Weill Cornell. His clinical fellowship training was completed at Montefiore Medical Center in the Bronx, New York.

About C.difficile:

It is the most common Healthcare-associated infection affecting an estimated 450,000 people annually in the United States alone with ~28,000 deaths from complications of this infection. This infection accounts for ~16% of all healthcare associated infections.

In the USA: Nearly half a million Americans suffer from Clostridioides difficile (C. diff.) infections in a single year according to a study released February 25, 2015 by the Centers for Disease Control and Prevention CDC).

**Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. Of those, about 15,000 deaths were estimated to be directly attributable to C. difficile infections (CDI), making C. difficile a very important cause of infectious disease death in the United States alone. More than 80 percent of the deaths associated with C. difficile occurred among Americans aged 65 years or older. C. difficile causes an inflammation of the colon and deadly diarrhea.

C Diff Foundation, a one hundred percent volunteer, world renowned 501(c)(3) not-for-profit organization, has appointed nationally renowned Gastroenterologist, Dr. Paul Feuerstadt as its first Director of Medical Education.

Related link: https://cdifffoundation.org/

New Research Sheds Light on Potential Role of Febrile Seizures and Other Risk Factors in Sudden Deaths in Children

ROSELAND, N.J. /ScoopCloud/ -- The SUDC Foundation highlights newly-published research from the Journal of American Medical Association (JAMA) that identifies an increased rate of febrile seizures among children who die suddenly, both with and without explanation. The authors of the article report the need for more research to identify febrile seizure patients at higher risk, as well as other potential risk factors of sudden death in children.

The published research, entitled "Sudden Deaths in Children: Potential Role of Febrile Seizures and Other Risk Factors," examined 391 cases of both Sudden Unexplained Death in Childhood (SUDC) and sudden, explained deaths in children between the ages of 1 and 6 years from 2001-2017. Among those studied, 28.8 percent of SUDC cases and 22.1 percent of sudden, explained cases also had a reported history of febrile seizures. In comparison, two to five percent of the general population experience febrile seizures. These findings mark the first time a significant increase in febrile seizures was found among sudden, explained child deaths.

"Sudden Unexplained Death in Childhood remains a tragic disorder that claims far too many lives and has been the subject of far too little research and public awareness," said Orrin Devinsky, M.D., of New York University Langone Health.

"This study has brought us closer to understanding the causes of some SUDC cases," said Daniel Friedman, M.D., of New York University Langone Health. "In the past decade, there have significant advances in understanding the mechanisms of seizure-related sudden death in people with epilepsy through animal models. This study provides the rational for extending these models to help identify risk biomarkers and preventative strategies for SUDC as well."

"I hope our analysis provides some reassurance to families who lost children to SUDC in that we did not identify a single case of unexplained sibling death," said Laura Gould Crandall, lead author and Executive Director and Co-founder of the SUDC Foundation. "To improve our understanding of SUDC, we need population-based studies where we examine cases that better reflect the general population and are informed by standardized investigations with additional testing, including genetic testing."

SUDC is a category of death in children over the age of one year which remains unexplained after a thorough investigation and autopsy. Most often, SUDC occurs in otherwise healthy children during sleep. At least 400 children are lost to SUDC in the United States every year.

The research also indicated the children in the study were over four times more likely to die during sleep in the SUDC cases as opposed to the sudden, explained cases. And none of the children studied had a sibling who also died prematurely from SUDC.

The full article will be available at 11 a.m. EDT on Friday, April 26, 2019.

To learn more about SUDC and the SUDC Foundation, please visit https://sudc.org/.

Additional information on "Sudden Deaths in Children: Potential Role of Febrile Seizures and Other Risk Factors": Data for this study was collected from 622 family members of children who died suddenly and unexpectedly and voluntarily registered with the SUDC Foundation. The family members provided the data evaluated through a comprehensive interview on medical and social histories and circumstances of death and forensic evaluations revealed an explained or unexplained cause of death (SUDC). Over 59 percent were male and the average age at death was 24.9 months.

About the SUDC Foundation:
The SUDC Foundation is the only organization worldwide whose purpose is to promote awareness, advocate for research and support those affected by SUDC. The SUDC Foundation provides all services at no cost to families.

The SUDC Foundation highlights newly-published research from the Journal of American Medical Association (JAMA) that identifies an increased rate of febrile seizures among children who die suddenly, both with and without explanation. The authors of the article report the need for more research.

Related link: https://sudc.org/

C Diff Foundation Hosts 3rd Annual Global C.diff. Awareness 2K Walks

TEANECK, N.J. /ScoopCloud/ -- C Diff Foundation announced today that registration is now open for the 3rd Annual Global C.diff. Awareness 2K Walks. The events, which will take place at the Morris A. Votee Park, Teaneck, N.J., Charlestown Township Park, Phoenixville, Pa., and Sims Park, New Port Richey, Fla., will be hosted by the C Diff Foundation on Saturday, May 18, 2019 from 8 a.m. - 12 p.m.

Dr. Martha Cloakie, PhD will be leading the walk in Leicester, U.K. on Friday, May 17, 2019.

All registered awareness walkers will receive t-shirts, giveaways, and educational material while introducing the communities to the resources available. C.diff. infections are one of the leading healthcare-associated infections facing local communities.

Registration is $20.00 per walker and children 10 years of age and under walk free. https://cdifffoundation.org/3rdannualwalk/

Proceeds from the events will benefit the C Diff Foundation's mission educating and advocating for C.difficile infection prevention, treatments, clinical trials, and environmental safety worldwide.

According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C.difficile), (formally known as Clostridium difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone."

Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

"Every day the C Diff Foundation members work to educate and advocate for C. difficile infection prevention, treatments, clinical trials, and environmental safety while providing support worldwide. Our dedication to the cause is making a difference as we share a common goal with government agencies and health care organizations witnessing a decrease in newly diagnosed C.diff. infections and saving lives. Our dedicated volunteering members, around the globe, are focused on improving the lives of individuals and families who are impacted by C.diff. infections," says Nancy Caralla, Founding President, and Executive Director of the C Diff Foundation.

We sincerely thank Vedanta Biosciences, Inc. for being the Diamond Sponsor of the 3rd Annual Global C.diff. Awareness 2K Walks. Vedanta Biosciences, Inc. is dedicated to finding treatments for patients with serious infections and immune diseases. Vedanta develops medicines made of consortia of bacterial strains which are selected to effect robust and durable changes in a patient's gut microbiota.

In contrast to fecal transplants or administration of fecal fractions, Vedanta's medicines are pure, uniform compositions of bacteria manufactured from clonal cell banks, bypassing the need to rely on direct sourcing of fecal donor material of inconsistent composition. Vedanta is currently enrolling patients with recurrent C. difficile infections (CDI) in its CONSORTIUM study to evaluate VE303, an investigational treatment for CDI.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) supports public health through educating and advocating for C. difficile infection prevention, treatments, clinical trials, and environmental safety worldwide. For more information, or to find out how you can be a host of a Global C.diff. Awareness 2K Walk visit http://www.cdifffoundation.org.

Follow C Diff Foundation on Twitter
@cdiffFoundation
#CdiffWalk2019

The C Diff Foundation announced today that registration is now open for the 3rd Annual Global C.diff. Awareness 2K Walks. The events, which will take place at the Morris A. Votee Park, Teaneck, N.J., Charlestown Township Park, Phoenixville, Pa., and Sims Park, New Port Richey, Fla., will be hosted by the C Diff Foundation on Saturday, May 18, 2019 from 8 a.m. - 12 p.m.

Related link: https://cdifffoundation.org/

The C Diff Foundation Has Declared an Urgent Need to Raise Clostridium difficile Infection Clinical Trial Awareness Worldwide

TAMPA, Fla. /ScoopCloud/ -- The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridioides difficile clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

Clostridioides difficile is also known as C.difficile, C.diff, CDI (Clostridioides difficile infection), CDAD (Clostridioides difficile-associated disease) and formally called Clostridium difficile.

In the USA: Nearly half a million Americans suffer from Clostridioides difficile (C. diff.) infections in a single year according to a study released in 2015 by the Centers for Disease Control and Prevention (CDC). Approximately 29,000 patients died within 30 days of the initial diagnosis of C. difficile. About 15,000 deaths were estimated to be directly attributable to C. difficile infections making it a very important cause of infectious disease death in the United States.

"The broad range of new therapies for Clostridium difficile (C.difficile) is being intensely studied in several essential global clinical trials. This continued research underpins the current clinical needs with both preventing and treating C.difficile," stated Glenn S. Tillitson, Ph.D., FRSM, FCCP.

Individuals volunteer to participate in clinical trials in hopes of improving their own health, to access treatments that might not be available otherwise, often because they are new and not yet widely available. They help others by contributing to advances in medicine. There can also be potential risks participating in clinical trials and clinical studies. All of the known risks associated with a particular trial and or study will be discussed during the informed consent process. It will be thoroughly explained in the informed consent document that a volunteer will receive from the research staff prior to participating in any study.

To learn more about clinical research (e.g., Clostridioides difficile formally Clostridium difficile, also known as C.diff. C.difficile. CDI, CDAD) visit the U.S. Food and Drug Administration https://www.fda.gov/ or telephone 1-800-835-4709, and visit https://clinicaltrials.gov/.

"Clinical trials are vital to improving our knowledge about how best to prevent and treat C. difficile infections. Informing patients of clinical trials is important, and in recent years several clinical trials have led to significant improvements in the treatments available for patients with C. difficile infections. Clinical trials are a vital way of making progress in our search for new therapies to prevent and treat a CDI," stated Mark Wilcox, MD, FRCPath, Consultant Microbiologist, Head of Microbiology and Academic Lead of Pathology Leeds Teaching Hospitals, Professor of Medical Microbiology University of Leeds Institute of Biomedical and Clinical Sciences, Lead on Clostridium difficile for Public Health England, UK.

About the U.S. Food and Drug Administration (FDA):

The FDA is responsible for protecting the public health by assuring that foods are safe, wholesome, sanitary and properly labeled; ensuring that human and veterinary drug, and vaccines and other biological products and medical devices intended for human use are safe and effective. FDA's responsibilities extend to the 50 United States, the District of Columbia, Puerto Rico, Guam, the Virgin Islands, American Samoa, and other U.S. territories and possessions.

About ClinicalTrials.gov:

ClinicalTrials.gov is a Web-based resource that provides patients, their family members, health care professionals, researchers, and the public with easy access to information on publicly and privately supported clinical studies on a wide range of diseases and conditions.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) non-profit, founded in 2012 with a global mission of providing education for C.difficile infection prevention, treatments, environmental safety and support through research being conducted by the government, industry, and academia and provide better advocacy on behalf of patients, healthcare professionals, and researchers worldwide.

For information please visit http://www.cdifffoundation.org/.

The C Diff Foundation announced today that their organization has implemented a global campaign to raise awareness of Clostridioides difficile clinical trials, clinical studies, clinical research and observational studies evaluating interventions for C. difficile prevention, treatments, and environmental safety.

Related link: https://cdifffoundation.org/

Neuroprosthetics Pioneer to Keynote at the 2018 Neurotech Leaders Forum in San Francisco

SAN FRANCISCO, Calif. /ScoopCloud/ -- Neurotech Reports today announced that the keynote speaker at the 18th annual Neurotech Leaders Forum will be Hunter Peckham, a pioneer in the field of neuroprosthetics, technology that restores movement for people living with paralysis.

Peckham is a Distinguished University Professor and Donnell Institute Professor of Biomedical Engineering at Case Western Reserve University. He is also associate director of technology transfer at the Cleveland FES Center and the founder of the Institute for Functional Restoration. The event will take place October 15-16 in San Francisco, Calif.

Frank Fischer, CEO of NeuroPace Inc., has also been added to the agenda as a keynote speaker. Other additions include Eddie Chang, co-director of the Center for Neural Engineering at UC Berkeley and UC San Francisco, Philip Starr, professor of neurosurgery at UCSF, Michael Ackermann, CEO of Presidio Medical, Bashar Badran from the U.S. Army Research Laboratories, Cristin Welle, a former FDA employee and now assistant professor at University of Colorado, Nick Langhals, Neural Engineering Program Manager at the National Institutes of Health, and John Donoghue, director of the Wyss Center for Neuro and Bioengineering.

Executives from several early-stage and emerging neurotech startups will also make presentations during the event. These include Manfred Franke, founder and CEO of Neuronoff Inc., Bill Edelman, chairman of Highland Instruments, Erik Nilsen, CEO of Bio-Signal Technologies, LLC, and Howard Leonhardt, CEO of CerebraCell.

The conference returns to the Embassy Suites San Francisco Airport-Waterfront in Burlingame, Calif. Platinum Sponsor at this year's conference will be Cirtec Medical. Micro Systems Technologies is the Gold Sponsor. Other sponsors include IMEC, Cactus Semiconductor, Hereaus, Senso Medical, RBrooks Group, Maynard Cooper, Cleveland FES Center, along with partners the International Neuromodulation Society and Neuromodec.

"We're pleased to have such a distinguished lineup of speakers at the 2018 Neurotech Leaders Forum," said James Cavuoto, editor and publisher of Neurotech Reports. Neurotech Reports, founded in 2001, is the leading and longest-established publishing and market-research firm covering the neurotechnology industry.

For more information, contact James Cavuoto at 415-546-1259 or visit http://www.neurotechreports.com/pages/leadersforum.html.

Neurotech Reports today announced that the keynote speaker at the 18th annual Neurotech Leaders Forum will be Hunter Peckham, a pioneer in the field of neuroprosthetics, technology that restores movement for people living with paralysis.

Related link: http://www.neurotechreports.com/

6th Annual International C.diff. Conference and Health EXPO in Philadelphia PA November 8-9

PHILADELPHIA, Pa. /ScoopCloud/ -- The C Diff Foundation is honored to welcome 20+ leading topic experts joined by Dale Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital and Mark Wilcox,B Med Sci, BM, BS, MD, FRCPath-, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT), Professor of Medical Microbiology at the University of Leeds, and Lead on Clostridium difficile for Public Health England (PHE).

Dale Gerding, MD, FACP, FIDSA and Mark Wilcox, B Med Sci, BM ,BS, MD, FRCPath- will be this year's Conference Chairs of the upcoming 6th Annual International "C.diff. Awareness Conference and Health EXPO," taking place on November 8 and 9, 2018 at the Embassy Suites by Hilton Philadelphia Airport - Philadelphia, Pennsylvania.

Dale Gerding, MD, FACP, FIDSA and Mark Wilcox,B Med Sci, BM, BS, MD, FRCPath- join the internationally recognized experts in health care, academic, and industry leaders to discuss the burden of Clostridium difficile infections (C.difficile, C.diff., CDI) Prevention, Treatments, Diagnostics, Research, Clinical Trials, with Microbiome Research, Infection Prevention, Sepsis Prevention, Environmental Safety, Fecal Microbiota Restoration, Antibiotic Stewardship, Scientific Poster Presentations and more.

To learn more about this extraordinary conference, agenda and guest speakers: https://cdifffoundation.org/2018-guest-speakers/

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

All attendees will have the highest levels of peer networking and learning opportunity at the International C.diff. Awareness Conference and Health EXPO. The conference program builds in time for face-to-face interaction between attending executives, corporate representatives and industry experts exhibiting in the health expo.

Attendee Barley Chironda, Infection Control Specialist, said about the 2017 conference, "I have attended all of the C Diff Foundation Conferences and I am always in awe at the wealth of new information that is presented at each conference. As an Infection Control Specialist, and a person who deals with Healthcare Infections, I feel this conference allows great knowledge sharing and networking."

With upmost appreciation we thank the following Exhibiting Sponsors for their continued support and partnering with the C Diff Foundation in promoting C. diff. Awareness worldwide:
- Diamond: Synthetic Biologics.
- Gold: Clorox Healthcare, Seres Therapeutics, ROCHE, Rebiotix, Pfizer.
- Silver: Mr. & Mrs. Angelo Ortiz.
- Bronze: Honey Bee Handiworks, Trinity Guardion, Steriliz, Safety Net America, SporeGen.

This conference is supported through an educational grant from Sanofi Pasteur US.

Visit https://cdifffoundation.org for more information. Contact Angelo Ortiz for registration, exhibiting/sponsor opportunities, and media partnerships: angelo.ortiz@cdifffoundation.org or Mobile (919) 201-1512.

About The C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100% volunteering professionals dedicated at supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide. Listen to "C.diff. Spores and More" Tuesday's at 1 p.m. ET (www.cdiffradio.com), sponsored by Clorox Healthcare, providing leading up-to-date information on topics that are in align with their mission.

Follow C Diff Foundation on LinkedIn, Facebook, and Instagram. Twitter @cdiffFoundation #Cdiff2018

The C Diff Foundation is honored to welcome 20+ leading topic experts joined by Dale Gerding, MD, FACP, FIDSA, Professor of Medicine at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois and Research Physician at the Edward Hines Jr. VA Hospital and Mark Wilcox, B Med Sci, BM, BS, MD, FRCPath-, Head of Microbiology and Academic Lead of Pathology at the Leeds Teaching Hospitals (LTHT).

Related link: https://cdifffoundation.org/

2nd Annual Global C.diff. Walks in US and UK to Raise Awareness on Importance of Clostridium difficile Infections Worldwide

TEANECK, N.J. /ScoopCloud/ -- Presented by the C Diff Foundation, the 2nd Annual Global C.diff. Awareness 2K Walks will take place on Saturday, May 19 at three separate locations: Morris A. Votee Park, Teaneck, New Jersey; Sims Park, New Port Richey, Florida; and in Leicester, England. All locations will include t-shirts and resourceful educational material for all registered walkers. The U.S. locations will also include water bottles and hydration stations.

According to the Centers for Disease Control and Prevention (CDC), Clostridium difficile infection (C. difficile) "has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone." Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.

The Global C. diff. Walks will raise awareness of

Clostridium difficile (C. diff.) infection prevention and provide educational material while introducing the communities to the resources available. C.diff. infections are one of the leading health issues facing local communities.

"Every day the C Diff Foundation works to educate and advocate for C. difficile infection prevention, treatments, environmental safety and support worldwide to save lives. Our dedicated volunteering members are focused on improving the lives of individuals and families that are impacted by a C.diff. infection," says Nancy Caralla, Founding President of the C Diff Foundation.

We sincerely thank the following Sponsors for their continued support and for joining the C Diff Foundation in promoting
C. diff. Awareness worldwide:
Platinum: CutisPharma, Inc.
Gold: Pfizer and Xenex Disinfection Services.
Silver: Quellthera.

Event Details:
When: Saturday, May 19, 2018 - "rain or shine."

Registration and Check-in takes place at 8 a.m. Walk and Program begins at 9 a.m. at: Milton A. Votee Park, Queen Anne Rd & Court St, Teaneck, NJ 07666; Sims Park, 6341 Bank Street, New Port Richey, FL 34652; and being led by Dr. Martha Cloakie, PhD, a walk in the park in Leicester, England.

To register on-line: https://cdifffoundation.org/ or https://cdifffoundation.org/2nd-annual-global-walks-2018/

Walkers can register individually ($20 per person) or as a team ($20 for team leader) and teams can recruit sponsors.

All proceeds raised will support the program of the C Diff Foundation which provides villages to cities with C. difficile infection education, advocacy, and support worldwide.

For additional information about the walk, please email info@cdifffoundation.org or call the main office in U.S.: (919) 201-1512.

About the C Diff Foundation:

The C Diff Foundation, a 501(c)(3) established 2012, comprised of 100 percent volunteering professionals who are dedicated supporting public health through education and advocating for C. difficile infection (CDI) prevention, treatments, environmental safety, and support worldwide.

Follow C Diff Foundation on Twitter
@cdiffFoundation
#CdiffWalk2018

Media Contact:
Angelo Ortiz, Global Walk Committee
angelo.ortiz@cdifffoundation.org

Presented by the C Diff Foundation, the 2nd Annual Global C.diff. Awareness 2K Walks will take place on Saturday, May 19 at three separate locations: Morris A. Votee Park, Teaneck, New Jersey; Sims Park, New Port Richey, Florida; and in Leicester, England. All locations will include t-shirts and resourceful educational material for all registered walkers. The U.S. locations will also include water bottles and hydration stations.

Related link: https://cdifffoundation.org/